10-Q
Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 10-Q

 

 

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2014

OR

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

COMMISSION FILE NUMBER 001-16789

 

 

 

LOGO

ALERE INC.

(Exact name of registrant as specified in its charter)

 

 

 

DELAWARE   04-3565120

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

51 SAWYER ROAD, SUITE 200

WALTHAM, MASSACHUSETTS 02453

(Address of principal executive offices) (Zip code)

(781) 647-3900

(Registrant’s telephone number, including area code)

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   x    Accelerated filer   ¨
Non-accelerated filer   ¨  (Do not check if a smaller reporting company)    Smaller reporting company   ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x

The number of shares outstanding of the registrant’s common stock, par value of $0.001 per share, as of May 1, 2014 was 82,592,966.

 

 

 


Table of Contents

ALERE INC.

REPORT ON FORM 10-Q

For the Quarterly Period Ended March 31, 2014

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Readers can identify these statements by forward-looking words such as “may,” “could,” “should,” “would,” “intend,” “will,” “expect,” “anticipate,” “believe,” “estimate,” “continue” or similar words. A number of important factors could cause actual results of Alere Inc. and its subsidiaries to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the risk factors detailed in Part I, Item 1A, “Risk Factors,” of our Annual Report on Form 10-K, as amended, for the fiscal year ended December 31, 2013 and other risk factors identified herein or from time to time in our periodic filings with the Securities and Exchange Commission. Readers should carefully review these risk factors, and should not place undue reliance on our forward-looking statements. These forward-looking statements are based on information, plans and estimates at the date of this report. We undertake no obligation to update any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or other changes.

Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to “we,” “us” and “our” refer to Alere Inc. and its subsidiaries.

TABLE OF CONTENTS

 

     PAGE  

PART I. FINANCIAL INFORMATION

     3   

Item 1. Financial Statements

     3   

a) Consolidated Statements of Operations for the Three Months Ended March 31, 2014 and 2013

     3   

b) Consolidated Statements of Comprehensive Loss for the Three Months Ended March 31, 2014 and 2013

     4   

c) Consolidated Balance Sheets as of March 31, 2014 and December 31, 2013

     5   

d) Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2014 and 2013

     6   

e) Notes to Consolidated Financial Statements

     7   

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

     29   

Item 3. Quantitative and Qualitative Disclosures About Market Risk

     37   

Item 4. Controls and Procedures

     37   

PART II. OTHER INFORMATION

     38   

Item 1A. Risk Factors

     38   

Item 6. Exhibits

     38   

SIGNATURE

     39   

 

2


Table of Contents

PART I—FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

ALERE INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

(in thousands, except per share amounts)

 

     Three Months Ended March 31,  
         2014             2013      

Net product sales

   $ 495,445      $ 508,276   

Services revenue

     215,965        226,909   
  

 

 

   

 

 

 

Net product sales and services revenue

     711,410        735,185   

License and royalty revenue

     5,212        4,064   
  

 

 

   

 

 

 

Net revenue

     716,622        739,249   
  

 

 

   

 

 

 

Cost of net product sales

     246,112        253,078   

Cost of services revenue

     117,732        120,158   
  

 

 

   

 

 

 

Cost of net product sales and services revenue

     363,844        373,236   

Cost of license and royalty revenue

     1,539        1,756   
  

 

 

   

 

 

 

Cost of net revenue

     365,383        374,992   
  

 

 

   

 

 

 

Gross profit

     351,239        364,257   
  

 

 

   

 

 

 

Operating expenses:

    

Research and development

     38,699        41,454   

Sales and marketing

     147,064        156,456   

General and administrative

     139,536        135,858   
  

 

 

   

 

 

 

Operating expenses

     325,299        333,768   
  

 

 

   

 

 

 

Operating income

     25,940        30,489   

Interest expense, including amortization of original issue discounts and deferred financing costs

     (52,044     (57,399

Other income (expense), net

     4,722        (470
  

 

 

   

 

 

 

Loss before benefit for income taxes

     (21,382     (27,380

Benefit for income taxes

     (9,917     (36,871
  

 

 

   

 

 

 

Income (loss) before equity earnings of unconsolidated entities, net of tax

     (11,465     9,491   

Equity earnings of unconsolidated entities, net of tax

     5,352        2,934   
  

 

 

   

 

 

 

Net income (loss)

     (6,113     12,425   

Less: Net income (loss) attributable to non-controlling interests

     108        (25
  

 

 

   

 

 

 

Net income (loss) attributable to Alere Inc. and Subsidiaries

     (6,221     12,450   

Preferred stock dividends

     (5,250     (5,250
  

 

 

   

 

 

 

Net income (loss) available to common stockholders

   $ (11,471   $ 7,200   
  

 

 

   

 

 

 

Basic net income (loss) per common share attributable to Alere Inc. and Subsidiaries:

   $ (0.14   $ 0.09   
  

 

 

   

 

 

 

Diluted net income (loss) per common share attributable to Alere Inc. and Subsidiaries:

   $ (0.14   $ 0.09   
  

 

 

   

 

 

 

Weighted-average shares-basic

     82,387        81,199   
  

 

 

   

 

 

 

Weighted-average shares-diluted

     82,387        81,300   
  

 

 

   

 

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

3


Table of Contents

ALERE INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(unaudited)

(in thousands)

 

     Three Months Ended March 31,  
         2014             2013      

Net income (loss)

   $ (6,113   $ 12,425   
  

 

 

   

 

 

 

Other comprehensive loss, before tax:

    

Changes in cumulative translation adjustment

     (11,340     (75,355

Unrealized losses on available for sale securities

     (17     —    

Unrealized gains on hedging instruments

     8        11   

Minimum pension liability adjustment

     74        605   
  

 

 

   

 

 

 

Other comprehensive loss, before tax

     (11,275     (74,739

Income tax benefit related to items of other comprehensive loss

     —         —    
  

 

 

   

 

 

 

Other comprehensive loss, net of tax

     (11,275     (74,739
  

 

 

   

 

 

 

Comprehensive loss

     (17,388     (62,314

Less: Comprehensive income (loss) attributable to non-controlling interests

     108        (25
  

 

 

   

 

 

 

Comprehensive loss attributable to Alere Inc. and Subsidiaries

   $ (17,496   $ (62,289
  

 

 

   

 

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

4


Table of Contents

ALERE INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(unaudited)

(in thousands, except par value amounts)

 

     March 31, 2014     December 31, 2013  
ASSETS     

Current assets:

    

Cash and cash equivalents

   $ 433,026      $ 361,908   

Restricted cash

     4,222        6,373   

Marketable securities

     781        858   

Accounts receivable, net of allowances of $78,054 and $76,643 at March 31, 2014 and December 31, 2013, respectively

     528,793        548,729   

Inventories, net

     371,136        364,185   

Deferred tax assets

     62,616        60,689   

Prepaid expenses and other current assets

     120,529        129,672   
  

 

 

   

 

 

 

Total current assets

     1,521,103        1,472,414   

Property, plant and equipment, net

     545,051        545,164   

Goodwill

     3,090,056        3,093,691   

Other intangible assets with indefinite lives

     55,916        56,702   

Finite-lived intangible assets, net

     1,617,254        1,684,611   

Restricted cash

     28,856        29,370   

Deferred financing costs, net, and other non-current assets

     80,056        84,073   

Investments in unconsolidated entities

     90,445        86,830   

Deferred tax assets

     7,449        7,959   
  

 

 

   

 

 

 

Total assets

   $ 7,036,186      $ 7,060,814   
  

 

 

   

 

 

 
LIABILITIES AND EQUITY     

Current liabilities:

    

Current portion of long-term debt

   $ 65,252      $ 49,112   

Current portion of capital lease obligations

     6,220        6,855   

Accounts payable

     190,448        187,371   

Accrued expenses and other current liabilities

     430,261        429,848   
  

 

 

   

 

 

 

Total current liabilities

     692,181        673,186   
  

 

 

   

 

 

 

Long-term liabilities:

    

Long-term debt, net of current portion

     3,745,796        3,772,788   

Capital lease obligations, net of current portion

     15,090        14,407   

Deferred tax liabilities

     307,574        329,249   

Other long-term liabilities

     194,989        188,336   
  

 

 

   

 

 

 

Total long-term liabilities

     4,263,449        4,304,780   
  

 

 

   

 

 

 

Commitments and contingencies (Note 16)

    

Stockholders’ equity:

    

Series B preferred stock, $0.001 par value (liquidation preference: $709,763 at March 31, 2014 and December 31, 2013); Authorized: 2,300 shares; Issued: 2,065 shares at March 31, 2014 and December 31, 2013; Outstanding: 1,774 shares at March 31, 2014 and December 31, 2013

     606,468        606,468   

Common stock, $0.001 par value; Authorized: 200,000 shares; Issued: 90,224 shares at March 31, 2014 and 89,666 shares at December 31, 2013; Outstanding: 82,545 shares at March 31, 2014 and 81,987 shares at December 31, 2013

     90        90   

Additional paid-in capital

     3,334,264        3,319,168   

Accumulated deficit

     (1,642,448     (1,636,227

Treasury stock, at cost, 7,679 shares at March 31, 2014 and December 31, 2013

     (184,971     (184,971

Accumulated other comprehensive loss

     (37,837     (26,562
  

 

 

   

 

 

 

Total stockholders’ equity

     2,075,566        2,077,966   

Non-controlling interests

     4,990        4,882   
  

 

 

   

 

 

 

Total equity

     2,080,556        2,082,848   
  

 

 

   

 

 

 

Total liabilities and equity

   $ 7,036,186      $ 7,060,814   
  

 

 

   

 

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

5


Table of Contents

ALERE INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(in thousands)

 

     Three Months Ended March 31,  
           2014              2013       

Cash Flows from Operating Activities:

    

Net income (loss)

   $ (6,113   $ 12,425   

Adjustments to reconcile net income (loss) to net cash provided by operating activities:

    

Non-cash interest expense, including amortization of original issue discounts and deferred financing costs

     4,141        5,217   

Depreciation and amortization

     98,086        104,970   

Non-cash charges for sale of inventories revalued at the date of acquisition

     —          461   

Non-cash stock-based compensation expense

     5,704        4,123   

Impairment of inventory

     589        —     

Impairment of long-lived assets

     161        —     

Loss on disposition of fixed assets

     2,072        172   

Equity earnings of unconsolidated entities, net of tax

     (5,352     (2,934

Deferred income taxes

     (24,636     (50,907

Other non-cash items

     (3,659     1,941   

Changes in assets and liabilities, net of acquisitions:

    

Accounts receivable, net

     19,898        (20,167

Inventories, net

     (12,745     (17,171

Prepaid expenses and other current assets

     4,330        (5,833

Accounts payable

     5,231        (1,988

Accrued expenses and other current liabilities

     8,363        42,096   

Other non-current liabilities

     13,313        795   

Cash paid for contingent consideration

     (3,475     (2,139
  

 

 

   

 

 

 

Net cash provided by operating activities

     105,908        71,061   
  

 

 

   

 

 

 

Cash Flows from Investing Activities:

    

(Increase) decrease in restricted cash

     2,151        (8,573

Purchases of property, plant and equipment

     (27,540     (36,105

Proceeds from sale of property, plant and equipment

     129        1,143   

Cash received from disposition

     4,373        —     

Cash paid for business acquisitions, net of cash acquired

     —          (158,421

Cash received from (paid for) investments

     (507     10,771   

Cash received from sales of marketable securities

     60        —     

Increase in other assets

     (2,925     (5,569
  

 

 

   

 

 

 

Net cash used in investing activities

     (24,259     (196,754
  

 

 

   

 

 

 

Cash Flows from Financing Activities:

    

Cash paid for financing costs

     (7     (1,427

Cash paid for contingent purchase price consideration

     (4,195     (19,098

Proceeds from issuance of common stock, net of issuance costs

     14,698        6,135   

Proceeds from issuance of long-term debt

     939        10,053   

Payments on long-term debt

     (15,823     (19,638

Net proceeds under revolving credit facilities

     233        162,483   

Cash paid for dividends

     (5,323     (5,323

Excess tax benefits on exercised stock options

     292        104   

Principal payments on capital lease obligations

     (1,840     (1,721
  

 

 

   

 

 

 

Net cash provided by (used in) financing activities

     (11,026     131,568   
  

 

 

   

 

 

 

Foreign exchange effect on cash and cash equivalents

     495        (6,988
  

 

 

   

 

 

 

Net increase (decrease) in cash and cash equivalents

     71,118        (1,113

Cash and cash equivalents, beginning of period

     361,908        328,346   
  

 

 

   

 

 

 

Cash and cash equivalents, end of period

   $ 433,026      $ 327,233   
  

 

 

   

 

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

6


Table of Contents

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

(1) Basis of Presentation of Financial Information

The accompanying Consolidated Financial Statements of Alere Inc. are unaudited. In the opinion of management, the unaudited Consolidated Financial Statements contain all adjustments considered normal and recurring and necessary for their fair statement. Interim results are not necessarily indicative of results to be expected for the year. These interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these Consolidated Financial Statements do not include all of the information and footnotes necessary for a complete presentation of financial position, results of operations, comprehensive income and cash flows. Our audited Consolidated Financial Statements for the year ended December 31, 2013 included information and footnotes necessary for such presentation and were included in our Annual Report on Form 10-K, as amended, filed with the Securities and Exchange Commission, or SEC, on March 3, 2014. These unaudited Consolidated Financial Statements should be read in conjunction with our audited Consolidated Financial Statements and notes thereto for the year ended December 31, 2013.

Certain reclassifications of prior period amounts have been made to conform to current period presentation. These reclassifications had no effect on net income or equity.

During the three months ended March 31, 2014, we recorded net after-tax expense charges of $1.3 million to correct prior period items, including a net after-tax charge of $2.8 million related to the fair value of the MedApps Holding Company, Inc., or MedApps, contingent consideration obligations. We consider the adjustments to be immaterial to both the prior period and the current period financial statements.

Certain amounts presented may not recalculate directly, due to rounding.

(2) Cash and Cash Equivalents

We consider all highly-liquid cash investments with original maturities of three months or less at the date of acquisition to be cash equivalents. At March 31, 2014, our cash equivalents consisted of money market funds.

(3) Restricted Cash

We had restricted cash of $33.1 million and $35.7 million as of March 31, 2014 and December 31, 2013, respectively. $28.9 million and $29.4 million of our restricted cash as of March 31, 2014 and December 31, 2013, respectively, was classified as non-current on our Consolidated Balance Sheet, as it secures a foreign bank loan arrangement that we entered into during the third quarter of 2013 and, under the terms of the loan agreement, is required to remain on deposit for two years.

(4) Inventories

Inventories are stated at the lower of cost (first in, first out) or market and are comprised of the following (in thousands):

 

     March 31, 2014      December 31, 2013  

Raw materials

   $ 124,020       $ 118,571   

Work-in-process

     73,848         79,559   

Finished goods

     173,268         166,055   
  

 

 

    

 

 

 
   $ 371,136       $ 364,185   
  

 

 

    

 

 

 

 

7


Table of Contents

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(unaudited)

 

(5) Stock-based Compensation

We recorded stock-based compensation expense in our Consolidated Statements of Operations for the three months ended March 31, 2014 and 2013, respectively, as follows (in thousands):

 

     Three Months Ended March 31,  
     2014     2013  

Cost of net revenue

   $ 287      $ 232   

Research and development

     1,191        747   

Sales and marketing

     891        716   

General and administrative

     3,335        2,428   
  

 

 

   

 

 

 
     5,704        4,123   

Benefit for income taxes

     (1,778     (862
  

 

 

   

 

 

 
   $ 3,926      $ 3,261   
  

 

 

   

 

 

 

(6) Net Income (Loss) per Common Share

The following table sets forth the computation of basic and diluted net income (loss) per common share for the three months ended March 31, 2014 and 2013 (in thousands, except per share amounts):

 

     Three Months Ended March 31,  
     2014     2013  

Basic and diluted net income (loss) per common share:

    

Numerator:

    

Net income (loss)

   $ (6,113   $ 12,425   

Preferred stock dividends

     (5,250     (5,250

Less: Net income (loss) attributable to non-controlling interest

     108        (25
  

 

 

   

 

 

 

Net income (loss) available to common stockholders

   $ (11,471   $ 7,200   
  

 

 

   

 

 

 

Denominator:

    

Weighted-average common shares outstanding—basic

     82,387        81,199   

Effect of dilutive securities:

    

Stock options

     —          101   
  

 

 

   

 

 

 

Weighted-average common shares outstanding—diluted

     82,387        81,300   
  

 

 

   

 

 

 

Basic net income (loss) per common share attributable to Alere Inc. and Subsidiaries

   $ (0.14   $ 0.09   
  

 

 

   

 

 

 

Diluted net income (loss) per common share attributable to Alere Inc. and Subsidiaries

   $ (0.14   $ 0.09   
  

 

 

   

 

 

 

The following potential dilutive securities were not included in the calculation of diluted net income (loss) per common share because the inclusion thereof would be antidilutive (in thousands):

 

     Three Months Ended March 31,  
     2014      2013  

Denominator:

     

Options to purchase shares of common stock

     11,143         9,987   

Warrants

     4         4   

Conversion shares related to 3% convertible senior subordinated notes

     3,411         3,411   

Conversion shares related to subordinated convertible promissory notes

     27         27   

Conversion shares related to Series B convertible preferred stock

     10,239         10,239   

Common stock equivalents related to the settlement of a contingent consideration obligation

     358         —     
  

 

 

    

 

 

 

Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding

     25,182         23,668   
  

 

 

    

 

 

 

 

8


Table of Contents

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(unaudited)

 

(7) Stockholders’ Equity and Non-controlling Interests

(a) Preferred Stock

For both the three months ended March 31, 2014 and 2013, Series B preferred stock dividends amounted to $5.3 million, which reduced earnings available to common stockholders for purposes of calculating net income (loss) per common share for each of the periods. As of March 31, 2014, $5.3 million of Series B preferred stock dividends was accrued. As of April 15, 2014, payments have been made covering all dividend periods through March 31, 2014.

The Series B preferred stock dividends for the three months ended March 31, 2014 and 2013 were paid in cash.

(b) Changes in Stockholders’ Equity and Non-controlling Interests

A summary of the changes in stockholders’ equity and non-controlling interests comprising total equity for the three months ended March 31, 2014 and 2013 is provided below (in thousands):

 

     Three Months Ended March 31,  
     2014     2013  
     Total
Stockholders’
Equity
    Non-
controlling
Interests
     Total
Equity
    Total
Stockholders’
Equity
    Non-
controlling
Interests
    Total
Equity
 

Equity, beginning of period

   $ 2,077,966      $ 4,882       $ 2,082,848      $ 2,180,422      $ 2,282      $ 2,182,704   

Issuance of common stock under employee compensation plans

     14,698        —           14,698        6,135        —          6,135   

Preferred stock dividends

     (5,323     —           (5,323     (5,323     —          (5,323

Stock-based compensation expense

     5,704        —           5,704        4,123        —          4,123   

Excess tax benefits on exercised stock options

     17        —           17        (422     —          (422

Net income (loss)

     (6,221     108         (6,113     12,450        (25     12,425   

Total other comprehensive loss

     (11,275     —           (11,275     (74,739     —          (74,739
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

Equity, end of period

   $ 2,075,566      $ 4,990       $ 2,080,556      $ 2,122,646      $ 2,257      $ 2,124,903   
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

(8) Business Combinations

Acquisitions are accounted for using the acquisition method and the acquired companies’ results have been included in the accompanying Consolidated Financial Statements from their respective dates of acquisition. During the three months ended March 31, 2014 and 2013, we expensed acquisition-related costs of $0.3 million and $0.9 million, respectively, in general and administrative expense.

Our business acquisitions have historically been made at prices above the fair value of the assets acquired and liabilities assumed, resulting in goodwill, based on our expectations of synergies and other benefits of combining the businesses. These synergies and benefits include elimination of redundant facilities, functions and staffing; use of our existing commercial infrastructure to expand sales of the products of the acquired businesses; and use of the commercial infrastructure of the acquired businesses to expand product sales in a cost-efficient manner.

Net assets acquired are recorded at their fair value and are subject to adjustment upon finalization of the fair value analysis. We are not aware of any information that indicates the final fair value analysis will differ materially from the preliminary estimates. The estimated useful lives of the individual categories of intangible assets were based on the nature of the applicable intangible asset and the expected future cash flows to be derived from the intangible asset. Amortization of intangible assets with finite lives is recognized over the shorter of the respective lives of the agreement or the period of time the intangible assets are expected to contribute to future cash flows. We amortize our finite-lived intangible assets based on patterns on which the respective economic benefits are expected to be realized.

 

9


Table of Contents

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(unaudited)

 

Acquisitions in 2013

(a) Epocal

On February 1, 2013, we acquired Epocal, Inc., or Epocal, located in Ottawa, Canada, a provider of technologies that support blood gas and electrolyte testing at the point of care. The aggregate purchase price was approximately $248.5 million, which consisted of $151.4 million in cash, a $22.1 million settlement of a pre-existing arrangement and a contingent consideration obligation with an aggregate acquisition date fair value of $75.0 million. The operating results of Epocal are included in our professional diagnostics reporting unit and business segment. The amount allocated to goodwill from this acquisition is not deductible for tax purposes.

(b) Other acquisitions in 2013

During the year ended December 31, 2013, we acquired the following businesses for a preliminary aggregate purchase price of $57.6 million, which included cash payments totaling $28.2 million, a $17.5 million settlement of a pre-existing arrangement, contingent consideration obligations with an aggregate acquisition date fair value of $1.3 million, deferred purchase price consideration with an acquisition date fair value of $0.8 million and an $8.0 million bargain purchase gain.

 

    certain assets of PT Mega Medika Mandiri, or Mega Medika, located in South Jakarta, Indonesia, a distributor of infectious disease products to the Indonesian marketplace as well as materials for vaccines to a pharmaceutical customer (Acquired January 2013)

 

    Discount Diabetic, LLC, or Discount Diabetic, located in Phoenix, Arizona, a provider of blood glucose monitoring products, including diabetes testing systems and test strips and other products (Acquired April 2013)

 

    the Medicare fee-for-service assets of Liberty Medical, or the Liberty business, located in Port St. Lucie, Florida, a leading mail order provider of diabetes testing supplies serving the needs of both Type 1 and Type 2 diabetic patients (Acquired April 2013)

 

    51% share in Cardio Selfcare B.V., subsequently renamed Alere Health Services B.V., or Alere Health Services, located in Ede, the Netherlands, a developer of innovative software for the healthcare industry that develops and licenses software and sells medical devices to enable patients to perform medical self-care, including thrombosis self-care (Acquired May 2013)

 

    74.9% interest in Pantech Proprietary Limited, or Pantech, located in Durban, South Africa, a supplier of rapid diagnostic test kits, including HIV, malaria, syphilis, drugs of abuse, 10 parameter urine sticks, glucometers and glucose sticks (Acquired July 2013)

 

    Certain assets of Simplex Healthcare, Inc. and its subsidiaries, or Simplex, located in Tennessee, a provider of home delivery of diabetes-related medical supplies and products (Acquired November 2013)

The operating results of Mega Medika, Discount Diabetic, the Liberty business, Alere Health Services, Pantech, and Simplex are included in our professional diagnostics reporting unit and business segment.

Our Consolidated Statement of Operations for the three months ended March 31, 2014 included revenue totaling approximately $23.8 million related to these businesses. Goodwill has been recognized in the Mega Medika, Alere Health Services, Pantech, and Simplex acquisitions and amounted to approximately $2.5 million. The goodwill related to the Mega Medika and Simplex acquisitions is deductible for tax purposes, but the goodwill related to the Pantech and Alere Health Services acquisitions is not.

With respect to our acquisition of the Liberty business, the purchase price of the acquisition has been allocated to the net tangible and intangible assets acquired, with the excess of the fair value of assets acquired over the purchase price recorded as a bargain purchase gain. The $8.0 million bargain purchase gain has been recorded in other income (expense), net in our consolidated statement of operations and is not recognized for tax purposes. The bargain purchase gain resulted from our operating cost structure which we believe will allow us to operate this business more cost effectively than the sellers.

 

10


Table of Contents

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(unaudited)

 

A summary of the preliminary fair values of the net assets acquired for the acquisitions consummated in 2013 is as follows (in thousands):

 

     Epocal      Other      Total  

Current assets (1)

   $ 12,536       $ 13,702       $ 26,238   

Property, plant and equipment

     1,267         1,669         2,936   

Goodwill

     98,454         2,543         100,997   

Intangible assets

     164,400         51,180         215,580   

Other non-current assets

     18,158         29         18,187   
  

 

 

    

 

 

    

 

 

 

Total assets acquired

     294,815         69,123         363,938   
  

 

 

    

 

 

    

 

 

 

Current liabilities

     2,627         5,398         8,025   

Non-current liabilities

     43,727         6,175         49,902   
  

 

 

    

 

 

    

 

 

 

Total liabilities assumed

     46,354         11,573         57,927   
  

 

 

    

 

 

    

 

 

 

Net assets acquired

     248,461         57,550         306,011   

Less:

        

Contingent consideration

     75,000         1,264         76,264   

Settlement of pre-existing arrangements

     22,088         17,500         39,588   

Non-controlling interest

     —           1,774         1,774   

Bargain purchase gain

     —           8,023         8,023   

Deferred purchase price consideration

     —           768         768   
  

 

 

    

 

 

    

 

 

 

Cash paid

   $ 151,373       $ 28,221       $ 179,594   
  

 

 

    

 

 

    

 

 

 

 

(1)  Includes approximately $3.3 million of acquired cash.

The following are the intangible assets acquired and their respective fair values and weighted-average useful lives (dollars in thousands):

 

     Epocal      Other      Total      Weighted-
average
Useful Life
 

Core technology and patents

   $ 119,700       $ —         $ 119,700         20.0 years   

Software

     —           2,154         2,154         5.7 years   

Trademarks and trade names

     20,500         80         20,580         19.1 years   

License agreements

     —           620         620         1.5 years   

Customer relationships

     —           42,510         42,510         11.5 years   

Other

     —           5,816         5,816         3.0 years   

In-process research and development

     24,200                 24,200         N/A   
  

 

 

    

 

 

    

 

 

    

Total intangible assets

   $ 164,400       $ 51,180       $ 215,580      
  

 

 

    

 

 

    

 

 

    

(9) Restructuring

The following table sets forth aggregate restructuring charges recorded in our Consolidated Statements of Operations for the three months ended March 31, 2014 and 2013 (in thousands):

 

     Three Months Ended March 31,  

Statement of Operations Caption

   2014      2013  

Cost of net revenue

   $ 875       $ 623   

Research and development

     —           —     

Sales and marketing

     1,557         1,099   

General and administrative

     4,783         2,170   
  

 

 

    

 

 

 

Total operating expenses

     7,215         3,892   

Interest expense, including amortization of original issue discounts and deferred financing costs

     125         55   
  

 

 

    

 

 

 

Total charges

   $ 7,340       $ 3,947   
  

 

 

    

 

 

 

 

11


Table of Contents

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(unaudited)

 

(a) 2014 Restructuring Plans

In 2014, management developed cost reduction efforts within our professional diagnostics and corporate and other business segments, including our U.S. sales force, our global information technology group, and certain businesses in Europe. The following table summarizes the restructuring activities related to our 2014 restructuring plans for the three months ended March 31, 2014 (in thousands):

 

     Professional Diagnostics      Corporate and Other      Total  

Severance-related costs

   $ 2,364       $ 87       $ 2,451   

Facility and transition costs

     34         8         42   
  

 

 

    

 

 

    

 

 

 

Cash charges

     2,398         95         2,493   

Fixed asset and inventory impairments

     750         —           750   
  

 

 

    

 

 

    

 

 

 

Total charges

   $ 3,148       $ 95       $ 3,243   
  

 

 

    

 

 

    

 

 

 

We anticipate incurring approximately $3.9 million and $1.3 million in additional costs under our 2014 restructuring plans related to our professional diagnostics and corporate and other business segments, respectively, in the U.S. and Europe and may develop additional plans over the remainder of 2014. As of March 31, 2014, $0.7 million in severance costs arising under our 2014 restructuring plans remain unpaid.

(b) 2013 Restructuring Plans

In 2013, management developed cost reduction efforts within our professional diagnostics business segment, including businesses in our United States, Europe and Asia Pacific regions. Additionally, management took steps to improve efficiencies within our health information solutions business segment, including winding down a small portion of this business, which resulted in charges associated with the impairment of related fixed and intangible assets. The following table summarizes the restructuring activities in our professional diagnostics and health information solutions business segments related to our 2013 restructuring plans for the three months ended March 31, 2014 and 2013 and since inception (in thousands):

 

     Three Months Ended March 31,      Since  

Professional Diagnostics

   2014      2013      Inception  

Severance-related costs

   $ 838       $ 833       $ 7,964   

Facility and transition costs

     174         13         2,755   
  

 

 

    

 

 

    

 

 

 

Cash charges

     1,012         846         10,719   

Fixed asset and inventory impairments

     —           —           743   
  

 

 

    

 

 

    

 

 

 

Total charges

   $ 1,012       $ 846       $ 11,462   
  

 

 

    

 

 

    

 

 

 

 

     Three Months Ended March 31,      Since  

Health Information Solutions

   2014     2013      Inception  

Severance-related costs

   $ 89      $ 69       $ 3,356   

Facility and transition costs

     3,227        —           6,182   

Other exit costs

     33        —           50   
  

 

 

   

 

 

    

 

 

 

Cash charges

     3,349        69         9,588   

Fixed asset and inventory impairments

     —          —           1,089   

Intangible asset impairments

     —          —           2,596   

Other non-cash (recoveries)

     (854     —           (1,757
  

 

 

   

 

 

    

 

 

 

Total charges

   $ 2,495      $ 69       $ 11,516   
  

 

 

   

 

 

    

 

 

 

We anticipate incurring approximately $2.4 million in additional costs under our 2013 restructuring plans related to our professional diagnostics business segment in the United States and Europe and approximately $0.7 million in additional facility costs under our 2013 restructuring plans related to our health information solutions segment. As of March 31, 2014, $7.4 million in severance and facility costs arising under our 2013 restructuring plans remain unpaid.

(c) Restructuring Plans Prior to 2013

In 2012, management developed cost reduction plans within our professional diagnostics business segment, including the integration of our businesses in Brazil, Europe and the United States. Additionally, management developed new plans to continue our efforts to reduce costs within our health information solutions business segment, including the termination of certain projects, which resulted in charges for the impairment of related fixed and intangible assets.

 

12


Table of Contents

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(unaudited)

 

In 2011, management executed a company-wide cost reduction plan, which impacted our corporate and other business segment, as well as the health information solutions and professional diagnostics business segments. Management also developed plans within our professional diagnostics business segment to consolidate operating activities among certain of our U.S., European and Asia Pacific subsidiaries, including transferring the manufacturing of our Panbio products from Australia to our Standard Diagnostics facility in South Korea and eliminating redundant costs among our newly acquired Axis-Shield subsidiaries. Additionally, within our health information solutions business segment, management executed plans to further reduce costs and improve efficiencies, as well as cease operations at our GeneCare Medical Genetics Center, Inc., facility in Chapel Hill, North Carolina and transfer the majority of our Quality Assured Services, Inc. operation in Orlando, Florida to our facility in Livermore, California.

In 2010, management developed several plans to reduce costs and improve efficiencies within our health information solutions and professional diagnostics business segments. Additionally in 2008, management developed and initiated plans to transition the businesses of Cholestech Corporation to our San Diego, California facility.

The following table summarizes the restructuring activities related to our active 2012, 2011, 2010 and 2008 restructuring plans for the three months ended March 31, 2014 and 2013 and since inception (in thousands):

 

     Three Months Ended March 31,     Since  

Professional Diagnostics

   2014      2013     Inception  

Severance-related costs

   $ 59       $ 312      $ 24,251   

Facility and transition costs

     84         232        8,846   

Other exit costs

     12         16        768   
  

 

 

    

 

 

   

 

 

 

Cash charges

     155         560        33,865   

Fixed asset and inventory impairments

     —          —         6,922   

Intangible asset impairments

     —          —         686   

Other non-cash charges

     —          —         64   
  

 

 

    

 

 

   

 

 

 

Total charges

   $ 155       $ 560      $ 41,537   
  

 

 

    

 

 

   

 

 

 
     Three Months Ended March 31,     Since  

Health Information Solutions

   2014      2013     Inception  

Severance-related costs

   $ —        $ 1,819     $ 12,308   

Facility and transition costs (recoveries)

     355        659       13,870   

Other exit costs

     80         39        843   
  

 

 

    

 

 

   

 

 

 

Cash charges (recoveries)

     435         2,517        27,021   

Fixed asset and inventory impairments

     —          —         3,878   

Intangible asset impairments

     —          —         5,923   

Other non-cash charges

     —          (45 )     (223
  

 

 

    

 

 

   

 

 

 

Total charges (recoveries)

   $ 435       $ 2,472      $ 36,599   
  

 

 

    

 

 

   

 

 

 

We anticipate incurring approximately $0.8 million in additional facility costs under these plans related to our professional diagnostics and health information solutions business segments. As of March 31, 2014, $4.9 million in cash charges remain unpaid, primarily related to facility lease obligations, which are anticipated to continue through 2020.

 

13


Table of Contents

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(unaudited)

 

(d) Restructuring Reserves

The following table summarizes our restructuring reserves related to the plans described above, of which $7.7 million is included in accrued expenses and other current liabilities and $5.3 million is included in other long-term liabilities on our accompanying Consolidated Balance Sheets (in thousands):

 

     Severance-
related
Costs
    Facility and
Transition
Costs
    Other Exit
Costs
    Total  

Balance, December 31, 2013

   $ 2,708      $ 7,830      $ 609      $ 11,147   

Cash charges

     3,437        3,882        125        7,444   

Payments

     (4,063     (1,459     (73     (5,595

Currency adjustments

     5        35       (9     31   
  

 

 

   

 

 

   

 

 

   

 

 

 

Balance, March 31, 2014

   $ 2,087      $ 10,288      $ 652      $ 13,027   
  

 

 

   

 

 

   

 

 

   

 

 

 

(10) Long-term Debt

We had the following long-term debt balances outstanding (in thousands):

 

     March 31,
2014
    December 31,
2013
 

A term loans(1) (2)

   $ 820,625      $ 832,188   

B term loans(1)

     901,875        904,188   

Incremental B-1 term loans(1)

     244,375        245,000   

Incremental B-2 term loans(1)

     194,629        195,050   

Revolving line of credit(1)

     170,000        170,000   

7.25% Senior notes

     450,000        450,000   

6.5% Senior subordinated notes

     425,000        425,000   

8.625% Senior subordinated notes

     400,000        400,000   

3% Convertible senior subordinated notes

     150,000        150,000   

Other lines of credit

     581        355   

Other

     53,963        50,119   
  

 

 

   

 

 

 
     3,811,048        3,821,900   

Less: Current portion

     (65,252     (49,112
  

 

 

   

 

 

 
   $ 3,745,796      $ 3,772,788   
  

 

 

   

 

 

 

 

(1)  Incurred under our secured credit facility.
(2)  Includes “A” term loans and “Delayed Draw” term loans under our secured credit facility.

In connection with our significant long-term debt issuances, we recorded interest expense, including amortization and write-offs of deferred financing costs and original issue discounts, in our accompanying Consolidated Statements of Operations for the three months ended March 31, 2014 and 2013, respectively, as follows (in thousands):

 

     Three Months Ended March 31,  
     2014      2013  

Secured credit facility (1)

   $ 24,762       $ 27,275   

7.25% Senior notes

     8,525         8,356   

7.875% Senior notes

     —           (27

6.5% Senior subordinated notes

     7,178         —    

9% Senior subordinated notes

     —           10,394   

8.625% Senior subordinated notes

     9,273         9,273   

3% Convertible senior subordinated notes

     1,246         1,246   
  

 

 

    

 

 

 
   $ 50,984       $ 56,517   
  

 

 

    

 

 

 

 

(1)  Includes “A” term loans, including the “Delayed-Draw” term loans; “B” term loans; “Incremental B-1” term loans; “Incremental B-2” term loans; and revolving line of credit loans. For the three months ended March 31, 2014 and 2013, the amounts include $0.4 million and $1.0 million, respectively, related to the amortization of fees paid for certain debt modifications.

 

14


Table of Contents

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(unaudited)

 

(11) Fair Value Measurements

We apply fair value measurement accounting to value our financial assets and liabilities. Fair value measurement accounting provides a framework for measuring fair value under U.S. GAAP and requires expanded disclosures regarding fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value.

Described below are the three levels of inputs that may be used to measure fair value:

Level 1—Quoted prices in active markets for identical assets or liabilities.

Level 2—Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2014 and December 31, 2013, and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value (in thousands):

 

Description

  March 31,
2014
    Quoted Prices in
Active Markets
(Level 1)
    Significant Other
Observable Inputs
(Level 2)
    Unobservable Inputs
(Level 3)
 

Assets:

       

Marketable securities

  $ 781      $ 781      $ —       $ —    
 

 

 

   

 

 

   

 

 

   

 

 

 

Total assets

  $ 781      $ 781      $ —       $ —    
 

 

 

   

 

 

   

 

 

   

 

 

 

Liabilities:

       

Contingent consideration obligations (1)

  $ 210,819      $ —       $ —       $ 210,819   
 

 

 

   

 

 

   

 

 

   

 

 

 

Total liabilities

  $ 210,819      $ —       $ —       $ 210,819   
 

 

 

   

 

 

   

 

 

   

 

 

 

Description

  December 31,
2013
    Quoted Prices in
Active Markets
(Level 1)
    Significant Other
Observable Inputs
(Level 2)
    Unobservable Inputs
(Level 3)
 

Assets:

       

Marketable securities

  $ 858      $ 858      $ —       $ —    
 

 

 

   

 

 

   

 

 

   

 

 

 

Total assets

  $ 858      $ 858      $ —       $ —    
 

 

 

   

 

 

   

 

 

   

 

 

 

Liabilities:

       

Contingent consideration obligations (1)

  $ 213,969      $ —       $ —       $ 213,969   
 

 

 

   

 

 

   

 

 

   

 

 

 

Total liabilities

  $ 213,969      $ —       $ —       $ 213,969   
 

 

 

   

 

 

   

 

 

   

 

 

 

 

(1)  We determine the fair value of the contingent consideration obligations based on a probability-weighted approach derived from earn-out criteria estimates and a probability assessment with respect to the likelihood of achieving the various earn-out criteria. The measurement is based upon significant inputs not observable in the market. Significant increases or decreases in any of these inputs could result in a significantly higher or lower fair value measurement. Changes in the fair value of these contingent consideration obligations are recorded as income or expense within operating income in our Consolidated Statements of Operations. See Note 16 for additional information on the valuation of our contingent consideration obligations.

 

15


Table of Contents

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(unaudited)

 

Changes in the fair value of our Level 3 contingent consideration obligations during the three months ended March 31, 2014 were as follows (in thousands):

 

Fair value of contingent consideration obligations, January 1, 2014

   $  213,969   

Payments

     (7,710

Present value accretion and adjustments

     4,550   

Foreign currency adjustments

     10   
  

 

 

 

Fair value of contingent consideration obligations, March 31, 2014

   $ 210,819   
  

 

 

 

At March 31, 2014 and December 31, 2013, the carrying amounts of cash and cash equivalents, restricted cash, receivables, accounts payable and other current liabilities approximated their estimated fair values.

The carrying amount and estimated fair value of our long-term debt were $3.8 billion and $3.9 billion, respectively, at March 31, 2014. The carrying amount and estimated fair value of our long-term debt were $3.8 billion and $3.9 billion, respectively, at December 31, 2013. The estimated fair value of our long-term debt was determined using market sources that were derived from available market information (Level 2 in the fair value hierarchy) and may not be representative of actual values that could have been or will be realized in the future.

(12) Defined Benefit Pension Plan

Our subsidiary in England, Unipath Ltd., has a defined benefit pension plan established for certain of its employees. The net periodic benefit costs are as follows (in thousands):

 

     Three Months Ended March 31,  
     2014     2013  

Service cost

   $ —       $ —    

Interest cost

     199        182   

Expected return on plan assets

     (188     (156

Amortization of prior service cost

     110        103   
  

 

 

   

 

 

 

Net periodic benefit cost

   $ 121      $ 129   
  

 

 

   

 

 

 

(13) Financial Information by Segment

Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision-making group is composed of the chief executive officer and members of senior management. Our reportable operating segments are professional diagnostics, health information solutions, consumer diagnostics and corporate and other. Our operating results include license and royalty revenue which are allocated to professional diagnostics and consumer diagnostics on the basis of the original license or royalty agreement. We evaluate performance of our operating segments based on revenue and operating income (loss). Segment information for the three months ended March 31, 2014 and 2013 is as follows (in thousands):

 

     Professional
Diagnostics
     Health
Information
Solutions
    Consumer
Diagnostics
     Corporate
and
Other
    Total  

Three Months Ended March 31, 2014:

            

Net revenue

   $ 566,545       $ 123,668      $ 26,409       $ —       $ 716,622   

Operating income (loss)

   $ 51,326       $ (6,720   $ 2,248       $ (20,914   $ 25,940   

Depreciation and amortization

   $ 77,421       $ 19,111      $ 920       $ 634      $ 98,086   

Restructuring charges

   $ 4,303       $ 2,817      $ —        $ 95      $ 7,215   

Stock-based compensation

   $ —        $ —       $ —        $ 5,704      $ 5.704   

Three Months Ended March 31, 2013:

            

Net revenue

   $ 582,492       $ 134,207      $ 22,550       $ —       $ 739,249   

Operating income (loss)

   $ 59,840       $ (13,893   $ 2,280       $ (17,738   $ 30,489   

Depreciation and amortization

   $ 82,794       $ 20,737      $ 1,153       $ 286      $ 104,970   

Non-cash charge associated with acquired inventory

   $ 461       $ —       $ —        $ —       $ 461   

Restructuring charges

   $ 1,389       $ 2,503      $ —        $ —       $ 3,892   

Stock-based compensation

   $ —        $ —       $ —        $ 4,123      $ 4,123   

Assets:

            

As of March 31, 2014

   $ 5,697,874       $ 496,310      $ 205,105       $ 636,897      $ 7,036,186   

As of December 31, 2013

   $ 5,744,734       $ 504,645      $ 197,458       $ 613,977      $ 7,060,814   

 

 

16


Table of Contents

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(unaudited)

 

The following tables summarize our net revenue from the professional diagnostics and health information solutions reporting segments by groups of similar products and services for the three months ended March 31, 2014 and 2013 (in thousands):

 

     Three Months Ended March 31,  

Professional Diagnostics Segment

   2014      2013  

Infectious disease

   $ 164,030       $ 189,844   

Toxicology

     151,897         149,049   

Cardiology

     121,633         114,933   

Diabetes

     50,721         50,083   

Other

     73,052         74,719   
  

 

 

    

 

 

 

Professional diagnostics net product sales and services revenue

     561,333         578,628   

License and royalty revenue

     5,212         3,864   
  

 

 

    

 

 

 

Professional diagnostics net revenue

   $ 566,545       $ 582,492   
  

 

 

    

 

 

 
     Three Months Ended March 31,  

Health Information Solutions Segment

   2014      2013  

Condition and case management

   $ 49,319       $ 54,126   

Wellness

     24,950         26,300   

Women’s & children’s health

     22,215         29,080   

Patient self-testing services

     27,184         24,701   
  

 

 

    

 

 

 

Health information solutions net revenue

   $ 123,668       $ 134,207   
  

 

 

    

 

 

 

(14) Related Party Transactions

In May 2007, we completed the formation of Swiss Precision Diagnostics GmbH, or SPD, our 50/50 joint venture with Procter & Gamble, for the development, manufacturing, marketing and sale of existing and to-be-developed consumer diagnostic products, outside the cardiology, diabetes and oral care fields. Upon completion of the arrangement to form the joint venture, we ceased to consolidate the operating results of our consumer diagnostic products business related to the joint venture and instead account for our 50% interest in the results of the joint venture under the equity method of accounting.

We had a net receivable from SPD of $0.2 million and $2.1 million as of March 31, 2014 and December 31, 2013, respectively. Included in the $0.2 million receivable balance as of March 31, 2014 is approximately $1.7 million of costs incurred in connection with our 2008 SPD-related restructuring plans. Included in the $2.1 million receivable balance as of December 31, 2013 is approximately $1.8 million of costs incurred in connection with our 2008 SPD-related restructuring plans. We have also recorded a long-term receivable totaling approximately $13.3 million and $13.2 million as of March 31, 2014 and December 31, 2013, respectively, related to the 2008 SPD-related restructuring plans. Additionally, customer receivables associated with revenue earned after the formation of the joint venture was completed have been classified as other receivables within prepaid and other current assets on our accompanying Consolidated Balance Sheets in the amount of $9.3 million and $12.4 million as of March 31, 2014 and December 31, 2013, respectively. In connection with the joint venture arrangement, the joint venture bears the collection risk associated with these receivables. Sales to the joint venture under our manufacturing agreement totaled $20.6 million and $17.1 million during the three-month periods ended March 31, 2014 and 2013, respectively. Additionally, services revenue generated pursuant to the long-term services agreement with the joint venture totaled $0.4 million and $0.3 million during the three-month periods ended March 31, 2014 and 2013, respectively. Sales under our manufacturing agreement and long-term services agreement are included in net product sales and services revenue, respectively, in our accompanying Consolidated Statements of Operations.

Under the terms of our product supply agreement, SPD purchases products from our manufacturing facilities in China. SPD in turn sells a portion of those tests back to us for final assembly and packaging. Once packaged, a portion of the tests are sold to P&G for distribution to third-party customers in North America. As a result of these related transactions, we have recorded $5.8 million and $9.4 million of trade receivables which are included in accounts receivable on our accompanying Consolidated Balance Sheets as of March 31, 2014 and December 31, 2013, respectively, and $22.2 million and $18.8 million of trade accounts

 

17


Table of Contents

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(unaudited)

 

payable which are included in accounts payable on our accompanying Consolidated Balance Sheets as of March 31, 2014 and December 31, 2013, respectively. During the three months ended March 31, 2013, we received $10.8 million in cash from SPD as a return of capital.

The following table summarizes our related party balances with SPD within our Consolidated Balance Sheets (in thousands):

 

Balance Sheet Caption

   March 31, 2014      December 31, 2013  

Accounts receivable, net of allowances

   $ 5,753       $ 9,436   

Prepaid expenses and other current assets

   $ 9,469       $ 12,417   

Deferred financing costs, net, and other non-current assets

   $ 13,313       $ 13,249   

Accounts payable

   $ 22,215       $ 18,811   

(15) Other Arrangements

On February 19, 2013, we entered into an agreement with the Bill and Melinda Gates Foundation, or the Gates Foundation, whereby we were awarded a grant by the Gates Foundation in the amount of $21.6 million to support the development and commercialization of a validated, low-cost, nucleic-acid assay for clinical Tuberculosis, or TB, detection and drug-resistance test cartridges and adaptation of an analyzer platform capable of operation in rudimentary laboratories in low-resource settings. In connection with this agreement, we also entered into a loan agreement with the Gates Foundation, or the Gates Loan Agreement, which provides for the making of subordinated term loans by the Gates Foundation to us from time to time, subject to the achievement of certain milestones, in an aggregate principal amount of up to $20.6 million. Funding under the Gates Loan Agreement will be used in connection with the purchase of equipment for an automated high-throughput manufacturing line and other uses as necessary for the manufacture of the TB and HIV-related products. All loans under the Gates Loan Agreement are evidenced by promissory notes that we have executed and delivered to the Gates Foundation, bear interest at the rate of 3% per annum and, except to the extent earlier repaid by us, mature and are required to be repaid in full on December 31, 2019. As of March 31, 2014, we had borrowed no amounts under the Gates Loan Agreement. As of March 31, 2014, we had received approximately $7.9 million in grant-related funding from the Gates Foundation, which was recorded as restricted cash and deferred grant funding. The deferred grant funding is classified within accrued expenses and other current liabilities on our accompanying Consolidated Balance Sheet. As qualified expenditures are incurred under the terms of the grant, we use the deferred funding to recognize a reduction of our related qualified research and development expenditures. For the three months ended March 31, 2014, we incurred $2.1 million of qualified expenditures, for which we reduced our deferred grant funding balance and recorded an offset to our research and development expenses.

(16) Material Contingencies

(a) Acquisition-related Contingent Consideration Obligations

We determine the acquisition date fair value of the contingent consideration obligations based on a probability-weighted approach derived from the overall likelihood of achieving certain performance targets, including product development milestones or financial metrics. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement, as defined in fair value measurement accounting. The resultant probability-weighted earn-out payments are discounted using a discount rate based upon the weighted-average cost of capital. At each reporting date, we revalue the contingent consideration obligations to the reporting date fair values and record increases and decreases in the fair values as income or expense in our Consolidated Statements of Operations.

Increases or decreases in the fair values of the contingent consideration obligations may result from changes in discount periods and rates, changes in the timing and amount of earn-out criteria and changes in probability assumptions with respect to the likelihood of achieving the various earn-out criteria.

 

18


Table of Contents

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(unaudited)

 

We have contractual contingent purchase price consideration obligations related to certain of our acquisitions, as follows (in thousands):

 

Acquisition

  Acquisition Date     Acquisition
Date Fair
Value
    Maximum
Remaining
Earn-out
Potential
as of
March 31,
2014
    Remaining
Earn-out
Period as
of
March 31,
2014
    Estimated
Fair Value as
of
March 31,
2014
    Estimated
Fair Value as
of
December 31,
2013
    Payments
Made
during
2014
 

TwistDx, Inc.

    March 11, 2010      $ 35,600      $ 123,888        2014 – 2025 (1)    $ 46,400      $ 45,502      $ 139   

Ionian Technologies, Inc.

    July 12, 2010      $ 24,500        57,500        2014 – 2015        29,400        29,000        —     

Laboratory Data Systems, Inc.

    August 29, 2011      $ 13,000        7,500        2013 (2)      7,500 (2)      7,400 (2)      —     

Forensics Limited (ROAR)

    September 22, 2011      $ 5,463        12,600        2014        3,328        2,484        —     

Method Factory Inc. (Wellogic)

    December 9, 2011      $ 18,900        (3)      2014 – 2019        25,400        26,900        150   

MedApps.

    July 2, 2012      $ 13,100        8,600        2014        7,600        8,200        5,000   

Amedica Biotech, Inc.

    July 3, 2012      $ 8,900        8,100        2013 (2)      7,935 (2)      7,500 (2)      —     

DiagnosisOne, Inc.

    July 31, 2012      $ 22,300        33,000        2014 – 2017        26,900        26,600        —     

Epocal.

    February 1, 2013      $ 75,000        65,500        2014 – 2018        45,600        47,200        —     

Other

    Various      $ 58,877        20,229        2014 – 2016        10,756        13,183        2,421   
         

 

 

   

 

 

   

 

 

 
          $ 210,819      $ 213,969      $ 7,710   
         

 

 

   

 

 

   

 

 

 

 

(1) The maximum earn-out period ends on the fifteenth anniversary of the acquisition date.
(2) The fair value of the maximum remaining earn-out was accrued as of March 31, 2014 and December 31, 2013. We expect to pay the maximum remaining earn-out during the second quarter of 2014.
(3)  The earn-out is comprised of three components of which two components have an aggregate maximum remaining earn-out potential of $49.9 million. There is no dollar cap on the third earn-out component, however, the earn-out potential is limited to the remaining earn-out period.

(17) Recent Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position, results of operations, comprehensive income or cash flows upon adoption.

Recently Adopted Standards

Effective January 1, 2014, we adopted Accounting Standards Update, or ASU, 2013-11, Presentation of an Unrecognized Tax Benefit when a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. ASU 2013-11 clarifies guidance and eliminates diversity in practice on the presentation of unrecognized tax benefits when a net operating loss carryforward, similar tax loss or a tax credit carryforward exists, with limited exceptions. The adoption of this standard had no material impact on our Consolidated Financial Statements.

(18) Equity Investments

We account for the results from our equity investments under the equity method of accounting in accordance with Accounting Standards Codification, or ASC, 323, Investments — Equity Method and Joint Ventures, based on the percentage of our ownership interest in the business. Our equity investments primarily include the following:

(a) SPD

We recorded earnings of $5.1 million and $2.5 million during the three months ended March 31, 2014 and 2013, respectively, in equity earnings of unconsolidated entities, net of tax, in our accompanying Consolidated Statements of Operations, which represented our 50% share of SPD’s net income for the respective periods.

(b) TechLab

We own 49% of TechLab, Inc., or TechLab, a privately-held developer, manufacturer and distributor of rapid non-invasive intestinal diagnostics tests in the areas of intestinal inflammation, antibiotic-associated diarrhea and parasitology. We recorded earnings of $0.3 million and $0.2 million during the three months ended March 31, 2014 and 2013, respectively, in equity earnings of unconsolidated entities, net of tax, in our accompanying Consolidated Statements of Operations, which represented our minority share of TechLab’s net income for the respective periods.

 

19


Table of Contents

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(unaudited)

 

Summarized financial information for SPD and TechLab on a combined basis is as follows (in thousands):

 

     Three Months Ended March 31,  

Combined Condensed Results of Operations:

   2014      2013  

Net revenue

   $ 48,933       $ 49,155   
  

 

 

    

 

 

 

Gross profit

   $ 42,980       $ 37,113   
  

 

 

    

 

 

 

Net income after taxes

   $ 10,830       $ 5,577   
  

 

 

    

 

 

 

Combined Condensed Balance Sheet:

   March 31, 2014      December 31, 2013  

Current assets

   $ 72,582       $ 63,985   

Non-current assets

     38,376         38,541   
  

 

 

    

 

 

 

Total assets

   $ 110,958       $ 102,526   
  

 

 

    

 

 

 

Current liabilities

   $ 38,524       $ 38,053   

Non-current liabilities

     6,430         6,175   
  

 

 

    

 

 

 

Total liabilities

   $ 44,954       $ 44,228   
  

 

 

    

 

 

 

(19) Guarantor Financial Information

Our 7.25% senior notes due 2018, our 8.625% senior subordinated notes due 2018, and our 6.5% senior subordinated notes due 2020 are guaranteed by certain of our consolidated wholly owned subsidiaries, or the Guarantor Subsidiaries. The guarantees are full and unconditional and joint and several. The following supplemental financial information sets forth, on a consolidating basis, balance sheets as of March 31, 2014 and December 31, 2013, the related statements of operations, statements of comprehensive income (loss) and cash flows for each of the three months ended March 31, 2014 and 2013, respectively, for Alere Inc., the Guarantor Subsidiaries and our other subsidiaries, or the Non-Guarantor Subsidiaries. The supplemental financial information reflects the investments of Alere Inc. and the Guarantor Subsidiaries in the Guarantor and Non-Guarantor Subsidiaries using the equity method of accounting.

We have extensive transactions and relationships between various members of the consolidated group. These transactions and relationships include intercompany pricing agreements, intellectual property royalty agreements and general and administrative and research and development cost-sharing agreements. Because of these relationships, it is possible that the terms of these transactions are not the same as those that would result from transactions among wholly unrelated parties.

For comparative purposes, certain amounts for prior periods have been reclassified to conform to the current period classification.

 

20


Table of Contents

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(unaudited)

 

CONSOLIDATING STATEMENT OF OPERATIONS

For the Three Months Ended March 31, 2014

(in thousands)

 

                 Non -              
           Guarantor     Guarantor              
     Issuer     Subsidiaries     Subsidiaries     Eliminations     Consolidated  

Net product sales

   $ —        $ 213,409      $ 336,037      $ (54,001   $ 495,445   

Services revenue

     —          197,908        18,057        —          215,965   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net product sales and services revenue

     —          411,317        354,094        (54,001     711,410   

License and royalty revenue

     —          3,485        5,018        (3,291     5,212   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net revenue

     —          414,802        359,112        (57,292     716,622   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cost of net product sales

     688        114,135        183,774        (52,485     246,112   

Cost of services revenue

     73        115,325        8,054        (5,720     117,732   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cost of net product sales and services revenue

     761        229,460        191,828        (58,205     363,844   

Cost of license and royalty revenue

     —          92        4,738        (3,291     1,539   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cost of net revenue

     761        229,552        196,566        (61,496     365,383   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit (loss)

     (761     185,250        162,546        4,204        351,239   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Operating expenses:

          

Research and development

     5,615        14,845        18,239        —          38,699   

Sales and marketing

     1,868        74,959        70,237        —          147,064   

General and administrative

     18,488        68,782        52,266        —          139,536   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Operating expenses

     25,971        158,586        140,742        —          325,299   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Operating income (loss)

     (26,732     26,664        21,804        4,204        25,940   

Interest expense, including amortization of original issue discounts and deferred financing costs

     (51,258     (5,628     (4,544     9,386        (52,044

Other income (expense), net

     4,694        3,648        5,825        (9,445     4,722   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) before provision (benefit) for income taxes

     (73,296     24,684        23,085        4,145        (21,382

Provision (benefit) for income taxes

     (38,423     17,367        9,681        1,458        (9,917
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax

     (34,873     7,317        13,404        2,687        (11,465

Equity in earnings of subsidiaries, net of tax

     28,355        68        —          (28,423     —     

Equity earnings of unconsolidated entities, net of tax

     405        —          5,064        (117     5,352   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net income (loss)

     (6,113     7,385        18,468        (25,853     (6,113

Less: Net income attributable to non-controlling interests

     —          —          108        —          108   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net income (loss) attributable to Alere Inc. and Subsidiaries

     (6,113     7,385        18,360        (25,853     (6,221

Preferred stock dividends

     (5,250     —          —          —          (5,250
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net income (loss) available to common stockholders

   $ (11,363   $ 7,385      $ 18,360      $ (25,853   $ (11,471
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

21


Table of Contents

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(unaudited)

 

CONSOLIDATING STATEMENT OF OPERATIONS

For the Three Months Ended March 31, 2013

(in thousands)

 

                Non -              
          Guarantor     Guarantor              
    Issuer     Subsidiaries     Subsidiaries     Eliminations     Consolidated  

Net product sales

  $ —        $ 233,551      $ 320,839      $ (46,114   $ 508,276   

Services revenue

    —          207,749        19,160        —          226,909   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net product sales and services revenue

    —          441,300        339,999        (46,114     735,185   

License and royalty revenue

    —          3,035        3,533        (2,504     4,064   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net revenue

    —          444,335        343,532        (48,618     739,249   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cost of net product sales

    948        121,236        172,574        (41,680     253,078   

Cost of services revenue

    —          115,971        8,142        (3,955     120,158   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cost of net product sales and services revenue

    948        237,207        180,716        (45,635     373,236   

Cost of license and royalty revenue

    —          17        4,243        (2,504     1,756   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cost of net revenue

    948        237,224        184,959        (48,139     374,992   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit (loss)

    (948     207,111        158,573        (479     364,257   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Operating expenses:

         

Research and development

    4,423        18,100        18,931        —          41,454   

Sales and marketing

    1,392        83,431        71,633        —          156,456   

General and administrative

    14,027        67,146        54,685        —          135,858   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Operating expenses

    19,842        168,677        145,249        —          333,768   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Operating income (loss)

    (20,790     38,434        13,324        (479     30,489   

Interest expense, including amortization of original issue discounts and deferred financing costs

    (56,858     (7,021     (3,417     9,897        (57,399

Other income (expense), net

    4,770        6,259        (1,603     (9,896     (470
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) before provision (benefit) for income taxes

    (72,878     37,672        8,304        (478     (27,380

Provision (benefit) for income taxes

    (62,811     17,082        8,971        (113     (36,871
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) before equity in earnings (losses) of subsidiaries and unconsolidated entities, net of tax

    (10,067     20,590        (667     (365     9,491   

Equity in earnings (losses) of subsidiaries, net of tax

    22,244        (614     —          (21,630     —     

Equity earnings of unconsolidated entities, net of tax

    248        —          2,688        (2     2,934   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net income

    12,425        19,976        2,021        (21,997     12,425   

Less: Net loss attributable to non-controlling interests

    —          —          (25     —          (25
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net income attributable to Alere Inc. and Subsidiaries

    12,425        19,976        2,046        (21,997     12,450   

Preferred stock dividends

    (5,250     —          —          —          (5,250
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net income available to common stockholders

  $ 7,175      $ 19,976      $ 2,046      $ (21,997   $ 7,200   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

22


Table of Contents

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(unaudited)

 

CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS)

For the Three Months Ended March 31, 2014

(in thousands)

 

                Non-              
          Guarantor     Guarantor              
    Issuer     Subsidiaries     Subsidiaries     Eliminations     Consolidated  

Net income (loss)

  $ (6,113   $ 7,386      $ 18,466      $ (25,852   $ (6,113
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income (loss), before tax:

         

Changes in cumulative translation adjustment

    157        (129     (11,368     —          (11,340

Unrealized losses on available for sale securities

    —          (17     —          —          (17

Unrealized gains on hedging instruments

    —          —          8        —          8   

Minimum pension liability adjustment

    —          —          74        —          74   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income (loss), before tax

    157        (146     (11,286     —          (11,275

Income tax benefit related to items of other comprehensive income (loss)

    —          —          —          —          —     
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income (loss), net of tax

    157        (146     (11,286     —          (11,275
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive income (loss)

    (5,956     7,240        7,180        (25,852     (17,388

Less: Comprehensive income attributable to non-controlling interests

    —          —          108        —          108   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries

  $ (5,956   $ 7,240      $ 7,072      $ (25,852   $ (17,496
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

23


Table of Contents

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(unaudited)

 

CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS)

For the Three Months Ended March 31, 2013

(in thousands)

 

                  Non -              
           Guarantor      Guarantor              
     Issuer     Subsidiaries      Subsidiaries     Eliminations     Consolidated  

Net income

   $ 12,425      $ 19,976       $ 2,021      $ (21,997   $ 12,425   
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

Other comprehensive loss, before tax:

           

Changes in cumulative translation adjustment

     (201     —           (75,154     —          (75,355

Unrealized gains on hedging instruments

     —          —           11        —          11   

Minimum pension liability adjustment

     —          —           605        —          605   
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

Other comprehensive loss, before tax

     (201     —           (74,538     —          (74,739

Income tax benefit related to items of other comprehensive loss

     —          —           —          —          —     
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

Other comprehensive loss, net of tax

     (201     —           (74,538     —          (74,739
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

Comprehensive income (loss)

     12,224        19,976         (72,517     (21,997     (62,314

Less: Comprehensive loss attributable to non-controlling interests

     —          —           (25     —          (25
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries

   $ 12,224      $ 19,976       $ (72,492   $ (21,997   $ (62,289
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

 

24


Table of Contents

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(unaudited)

 

CONSOLIDATING BALANCE SHEET

March 31, 2014

(in thousands)

 

          Guarantor     Non-Guarantor              
    Issuer     Subsidiaries     Subsidiaries     Eliminations     Consolidated  

ASSETS

         

Current assets:

         

Cash and cash equivalents

  $ 13,020      $ 82,048      $ 337,958      $ —        $ 433,026   

Restricted cash

    84        2,915        1,223        —          4,222   

Marketable securities

    —          776        5        —          781   

Accounts receivable, net of allowances

    —          250,603        278,190        —          528,793   

Inventories, net

    —          170,165        218,246        (17,275     371,136   

Deferred tax assets

    4,984        27,375        32,120        (1,863     62,616   

Prepaid expenses and other current assets

    538,410        (432,500     10,713        3,906        120,529   

Intercompany receivables

    304,817        715,596        69,903        (1,090,316     —     
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total current assets

    861,315        816,978        948,358        (1,105,548     1,521,103   

Property, plant and equipment, net

    19,312        286,490        239,523        (274     545,051   

Goodwill

    —          1,842,309        1,247,747        —          3,090,056   

Other intangible assets with indefinite lives

    —          14,300        41,675        (59     55,916   

Finite-lived intangible assets, net

    10,245        959,002        648,007        —          1,617,254   

Restricted cash

    —          —          28,856        —          28,856   

Deferred financing costs, net and other non-current assets

    51,746        7,586        20,764        (40     80,056   

Investments in subsidiaries

    3,821,577        270,857        191,920        (4,284,354     —     

Investments in unconsolidated entities

    30,174        —          49,510        10,761        90,445   

Deferred tax assets

    —          —          7,449        —          7,449   

Intercompany notes receivables

    1,099,817        720,017        48,779        (1,868,613     —     
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total assets

  $ 5,894,186      $ 4,917,539      $ 3,472,588      $ (7,248,127   $ 7,036,186   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

LIABILITIES AND EQUITY

         

Current liabilities:

         

Current portion of long-term debt

  $ 60,000      $ 962      $ 4,290      $ —        $ 65,252   

Current portion of capital lease obligations

    —          3,165        3,055        —          6,220   

Accounts payable

    8,280        79,319        102,849        —          190,448   

Accrued expenses and other current liabilities

    85,170        161,351        183,775        (35     430,261   

Intercompany payables

    660,712        148,533        281,071        (1,090,316     —     
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total current liabilities

    814,162        393,330        575,040        (1,090,351     692,181   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Long-term liabilities:

         

Long-term debt, net of current portion

    3,705,215        100        40,481        —          3,745,796   

Capital lease obligations, net of current portion

    —          5,563        9,527        —          15,090   

Deferred tax liabilities

    (65,370     290,283        82,616        45        307,574   

Other long-term liabilities

    25,384        61,026        108,619        (40     194,989   

Intercompany notes payables (receivables)

    (660,771     1,419,782        1,109,602        (1,868,613     —     
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total long-term liabilities

    3,004,458        1,776,754        1,350,845        (1,868,608     4,263,449   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Stockholders’ equity

    2,075,566        2,747,455        1,541,713        (4,289,168     2,075,566   

Non-controlling interests

    —          —          4,990        —          4,990   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total equity

    2,075,566        2,747,455        1,546,703        (4,289,168     2,080,556   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total liabilities and equity

  $ 5,894,186      $ 4,917,539      $ 3,472,588      $ (7,248,127   $ 7,036,186   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

25


Table of Contents

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(unaudited)

 

CONSOLIDATING BALANCE SHEET

December 31, 2013

(in thousands)

 

          Guarantor     Non-Guarantor              
    Issuer     Subsidiaries     Subsidiaries     Eliminations     Consolidated  

ASSETS

         

Current assets:

         

Cash and cash equivalents

  $ 14,801      $ 85,453      $ 261,654      $ —        $ 361,908   

Restricted cash

    2,221        2,915        1,237        —          6,373   

Marketable securities

    —          853        5        —          858   

Accounts receivable, net of allowances

    —          238,782        309,947        —          548,729   

Inventories, net

    —          168,058        219,892        (23,765     364,185   

Deferred tax assets

    5,191        20,541        31,451        3,506        60,689   

Prepaid expenses and other current assets

    512,123        (405,954     23,547        (44     129,672   

Intercompany receivables

    317,357        759,497        75,424        (1,152,278     —     
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total current assets

    851,693        870,145        923,157        (1,172,581     1,472,414   

Property, plant and equipment, net

    15,086        288,637        241,737        (296     545,164   

Goodwill

    —          1,841,377        1,252,314        —          3,093,691   

Other intangible assets with indefinite lives

    —          14,300        42,402        —          56,702   

Finite-lived intangible assets, net

    11,006        995,868        677,737        —          1,684,611   

Restricted cash

    —          —          29,370        —          29,370   

Deferred financing costs, net and other non-current assets

    55,207        8,353        20,559        (46     84,073   

Investments in subsidiaries

    3,802,475        267,824        191,947        (4,262,246     —     

Investments in unconsolidated entities

    29,005        —          44,637        13,188        86,830   

Deferred tax assets

    —          —          7,959        —          7,959   

Intercompany notes receivables (payables)

    1,100,746        630,628        (741,016     (990,358     —     
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total assets

  $ 5,865,218      $ 4,917,132      $ 2,690,803      $ (6,412,339   $ 7,060,814   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

LIABILITIES AND EQUITY

         

Current liabilities:

         

Current portion of long-term debt

  $ 45,000      $ 323      $ 3,789      $ —        $ 49,112   

Current portion of capital lease obligations

    —          3,751        3,104        —          6,855   

Accounts payable

    12,584        69,076        105,711        —          187,371   

Accrued expenses and other current liabilities

    63,990        164,762        201,132        (36     429,848   

Intercompany payables

    728,541        149,031        274,707        (1,152,279     —     
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total current liabilities

    850,115        386,943        588,443        (1,152,315     673,186   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Long-term liabilities:

         

Long-term debt, net of current portion

    3,735,137        100        37,551        —          3,772,788   

Capital lease obligations, net of current portion

    —          5,938        8,469        —          14,407   

Deferred tax liabilities

    (43,246     284,448        88,039        8        329,249   

Other long-term liabilities

    19,753        58,823        109,806        (46     188,336   

Intercompany notes payables (receivables)

    (774,507     1,444,741        320,125        (990,359     —     
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total long-term liabilities

    2,937,137        1,794,050        563,990        (990,397     4,304,780   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Stockholders’ equity

    2,077,966        2,736,139        1,533,488        (4,269,627     2,077,966   

Non-controlling interests

    —          —          4,882        —          4,882   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total equity

    2,077,966        2,736,139        1,538,370        (4,269,627     2,082,848   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total liabilities and equity

  $ 5,865,218      $ 4,917,132      $ 2,690,803      $ (6,412,339   $ 7,060,814   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

26


Table of Contents

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(unaudited)

 

CONSOLIDATING STATEMENT OF CASH FLOWS

For the Three Months Ended March 31, 2014

(in thousands)

 

          Guarantor     Non-Guarantor              
    Issuer     Subsidiaries     Subsidiaries     Eliminations     Consolidated  

Cash Flows from Operating Activities:

         

Net income (loss)

  $ (6,113   $ 7,385      $ 18,468      $ (25,853   $ (6,113

Adjustments to reconcile net income (loss) to net cash provided by operating activities:

         

Equity in earnings of subsidiaries, net of tax

    (28,355     (68     —          28,423        —     

Non-cash interest expense, including amortization of original issue discounts and deferred financing costs

    3,857        125        159        —          4,141   

Depreciation and amortization

    1,399        58,445        38,166        76        98,086   

Non-cash stock-based compensation expense

    2,407        1,093        2,204        —          5,704   

Impairment of inventory

    —          —          589        —          589   

Impairment of long-lived assets

    —          —          161        —          161   

Loss on sale of fixed assets

    —          2,010        62        —          2,072   

Equity earnings of unconsolidated entities, net of tax

    (405     —          (5,064     117        (5,352

Deferred income taxes

    (21,658     (1,399     (3,037     1,458        (24,636

Other non-cash items

    —          1,197        (4,856     —          (3,659

Changes in assets and liabilities, net of acquisitions:

         

Accounts receivable, net

    —          (11,821     31,719        —          19,898   

Inventories, net

    —          (8,576     (105     (4,064     (12,745

Prepaid expenses and other current assets

    (26,287     23,130        11,790        (4,303     4,330   

Accounts payable

    (4,305     11,975        (2,439     —          5,231   

Accrued expenses and other current liabilities

    18,625        (3,339     (7,278     355        8,363   

Other non-current liabilities

    9,106        2,148        (1,895     3,954        13,313   

Cash paid for contingent consideration

    (3,417     —          (58     —          (3,475

Intercompany payable (receivable)

    67,749        (70,945     3,196        —          —     
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net cash provided by operating activities

    12,603        11,360        81,782        163        105,908   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cash Flows from Investing Activities:

         

Decrease in restricted cash

    2,125        —          26        —          2,151   

Purchases of property, plant and equipment

    (6,323     (12,941     (9,093     817        (27,540

Proceeds from sale of property, plant and equipment

    269        664        112        (916     129   

Cash received from disposition

    —          —          4,373        —          4,373   

Cash paid for investments

    (504     —          (3     —          (507

Cash received from sales of marketable securities

    —          60        —          —          60   

Increase in other assets

    (311     (2,185     (482     53        (2,925
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net cash used in investing activities

    (4,744     (14,402     (5,067     (46     (24,259
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cash Flows from Financing Activities:

         

Cash paid for financing costs

    (7     —          —          —          (7

Cash paid for contingent purchase price consideration

    (4,072     —          (123     —          (4,195

Proceeds from issuance of common stock, net of issuance costs

    14,698        —          —          —          14,698   

Proceeds from issuance of long-term debt

    —          939        —          —          939   

Payments on long-term debt

    (15,000     (301     (522     —          (15,823

Net proceeds under revolving credit facilities

    —          —          233        —          233   

Cash paid for dividends

    (5,323     —          —          —          (5,323

Excess tax benefits on exercised stock options

    53        207        32        —          292   

Principal payments on capital lease obligations

    —          (1,080     (760     —          (1,840
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net cash used in financing activities

    (9,651     (235     (1,140     —          (11,026
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Foreign exchange effect on cash and cash equivalents

    11        (128     729        (117     495   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net increase (decrease) in cash and cash equivalents

    (1,781     (3,405     76,304        —          71,118   

Cash and cash equivalents, beginning of period

    14,801        85,453        261,654        —          361,908   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cash and cash equivalents, end of period

  $ 13,020      $ 82,048      $ 337,958      $ —        $ 433,026   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

27


Table of Contents

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(unaudited)

 

CONSOLIDATING STATEMENT OF CASH FLOWS

For the Three Months Ended March 31, 2013

(in thousands)

 

          Guarantor     Non-Guarantor              
    Issuer     Subsidiaries     Subsidiaries     Eliminations     Consolidated  

Cash Flows from Operating Activities:

         

Net income

  $ 12,425      $ 19,976      $ 2,021      $ (21,997   $ 12,425   

Adjustments to reconcile net income to net cash provided by (used in) operating activities:

         

Equity in earnings (losses) of subsidiaries, net of tax

    (22,244     614        —          21,630        —     

Non-cash interest expense, including amortization of original issue discounts and deferred financing costs

    5,153        55        9        —          5,217   

Depreciation and amortization

    1,287        62,711        41,001        (29     104,970   

Non-cash charges for sale of inventories revalued at the date of acquisition

    —          —          461        —          461   

Non-cash stock-based compensation expense

    1,660        1,096        1,367        —          4,123   

(Gain) loss on sale of fixed assets

    —          227        (55     —          172   

Equity earnings of unconsolidated entities, net of tax

    (248     —          (2,688     2        (2,934

Deferred income taxes

    (30,889     (10,300     (9,605     (113     (50,907

Other non-cash items

    (762     275        2,428        —          1,941   

Changes in assets and liabilities, net of acquisitions:

         

Accounts receivable, net

    —          (1,968     (18,199     —          (20,167

Inventories, net

    —          (10,617     (7,129     575        (17,171

Prepaid expenses and other current assets

    (473,927     413,274        35,633        19,187        (5,833

Accounts payable

    (604     (7,823     6,439        —          (1,988

Accrued expenses and other current liabilities

    478,784        (387,671     (29,830     (19,187     42,096   

Other non-current liabilities

    (126     (2,959     3,880        —          795   

Cash paid for contingent consideration

    (2,139     —          —          —          (2,139

Intercompany payable (receivable)

    64,910        (77,486     12,576        —          —     
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net cash provided by (used in) operating activities

    33,280        (596     38,309        68        71,061   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cash Flows from Investing Activities:

         

Increase in restricted cash

    (7,933     (630     (10     —          (8,573

Purchases of property, plant and equipment

    (37     (14,732     (26,358     5,022        (36,105

Proceeds from sale of property, plant and equipment

    —          2,106        4,085        (5,048     1,143   

Cash paid for acquisitions, net of cash acquired

    (151,372     —          (7,049     —          (158,421

Cash received from investments

    —          —          10,771        —          10,771   

Increase in other assets

    (3,210     (881     (1,478     —          (5,569
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net cash used in investing activities

    (162,552     (14,137     (20,039     (26     (196,754
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cash Flows from Financing Activities:

         

Cash paid for financing costs

    (1,427     —          —          —          (1,427

Cash paid for contingent purchase price consideration

    (19,098     —          —          —          (19,098

Proceeds from issuance of common stock, net of issuance costs

    6,135        —          —          —          6,135   

Proceeds from issuance of long-term debt

    —          1,007        9,046        —          10,053   

Payments on long-term debt

    (16,845     (445     (2,348     —          (19,638

Net proceeds (payments) under revolving credit facilities

    170,000        —          (7,517     —          162,483   

Cash paid for dividends

    (5,323     —          —          —          (5,323

Excess tax benefits on exercised stock options

    71        17        16        —          104   

Principal payments on capital lease obligations

    —          (817     (904     —          (1,721
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net cash provided by (used in) financing activities

    133,513        (238     (1,707     —          131,568   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Foreign exchange effect on cash and cash equivalents

    762        16        (7,724     (42     (6,988
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net increase (decrease) in cash and cash equivalents

    5,003        (14,955     8,839        —          (1,113

Cash and cash equivalents, beginning of period

    3,623        67,941        256,782        —          328,346   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cash and cash equivalents, end of period

  $ 8,626      $ 52,986      $ 265,621      $ —        $ 327,233   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

28


Table of Contents
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Statements

This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You can identify these statements by forward-looking words such as “may,” “could,” “should,” “would,” “intend,” “will,” “expect,” “anticipate,” “believe,” “estimate,” “continue” or similar words. You should read statements that contain these words carefully because they discuss our future expectations, contain projections of our future results of operations or of our financial condition or state other “forward-looking” information. Forward-looking statements include, without limitation, statements regarding anticipated expansion and growth in certain of our product and service offerings, the impact of our research and development activities, potential new product and technology achievements, the potential for selective acquisitions, including acquisitions of health information solutions businesses outside the United States, the impact of potential divestitures of non-core assets, including our planned initial public offering of ordinary shares of BBI Diagnostics Group plc, or BBI Diagnostics, the effect of initiatives to reduce healthcare expenses, our ability to improve our working capital and operating margins, our expectations with respect to Apollo, our integrated health information solutions technology platform, our ability to improve care and lower healthcare costs for both providers and patients, and our funding plans for our future working capital needs and commitments. Actual results or developments could differ materially from those projected in such statements as a result of numerous factors, including, without limitation, those risks and uncertainties set forth in Part I, Item 1A, “Risk Factors,” of our Annual Report on Form 10-K, as amended, for the year ended December 31, 2013 and other risk factors identified herein or from time to time in our periodic filings with the SEC. We do not undertake any obligation to update any forward-looking statements. This report and, in particular, the following discussion and analysis of our financial condition and results of operations, should be read in light of those risks and uncertainties and in conjunction with our accompanying Consolidated Financial Statements and notes thereto.

Overview

We empower individuals to take greater control of their health at home, under the supervision of their healthcare providers, by connecting innovative diagnostics in the hands of patients to their healthcare providers. We are a leading global provider of diagnostic products that deliver rapid and accurate results at the point of care, with particular emphasis in the fields of infectious diseases, toxicology, cardiology and diabetes. Our connected device technologies and health information solutions give providers the ability to speed up and customize treatment by enabling timely access to actionable data, from both our connected devices and our personal and electronic health record solutions, as well as decision-support software and analytic tools. Through our health information solutions business, we also offer programs for chronic condition management, coagulation monitoring, smoking cessation, pregnancy management, weight loss and healthy living. Our connected health approach envisions a healthcare system that unites patients with diagnostic tools at their fingertips with providers and payers in a model that provides patients with a better quality of life and improved outcomes, while simultaneously reducing healthcare costs to the system.

Having substantially completed the foundation of our business, during 2013 and the first quarter of 2014 we focused on initiatives to re-establish historic organic revenue growth rates in our point-of-care diagnostics business, and improving our operational efficiency with the goal of generating more predictable earnings growth and sustainable, strong cash flow.

Our revenue growth has been impacted by supply challenges for certain of our Alere Triage product lines arising from an FDA inspection of our San Diego facility in 2012. We have overcome most of these supply challenges, and we are now consistently supplying the market with all Alere Triage products, other than our shortness-of-breath panel, which we expect to return to the market during the second quarter of 2014. During 2013, we also continued to increase our market presence with Accountable Care Organizations through our integrated product and service offerings. Our continuing expansion in the growing markets of Asia, Latin America and Africa should also improve organic growth rates over the longer term.

In addition, we expect our new product launches in 2013 to contribute to improved organic growth rates in the future. In January 2014, we also announced that the Alere i Influenza A & B test, the first and only commercially available molecular test to detect and differentiate influenza A and B virus in less than 15 minutes, had been launched in Austria, France, Spain, Switzerland, Germany, Italy and the U.K. The Alere i test remains under FDA review and is not yet available for sale in the United States. During 2013, we also made significant progress towards the anticipated launch of Alere Q in Africa during the first half of 2014. Alere Q enables molecular viral load testing for HIV at the point of care and applications for HCV and tuberculosis are in development for the Alere Q platform.

Since late 2012 we have taken important steps to build our global enterprise infrastructure, which we believe will enable us to realize more predictable earnings growth and stronger, more sustainable cash flow. During 2013, we standardized a number of our key business processes. Most notably, we began implementation of a global ERP system for many of our business units in the U.S. and Europe, which we have recently completed. We also implemented a global sourcing initiative based in the Philippines, which has enabled a more cost effective scaling of our mail order diabetes business to serve over 769,000 patients. We are already expanding this initiative to include our Alere Home Monitoring business, which we expect to result in further cost efficiencies.

 

29


Table of Contents

We remain engaged in active and ongoing discussions concerning divestitures of our non-core businesses. During 2013, we completed the sale of one such non-core asset and used $27.5 million of the proceeds from the transaction to repay indebtedness. In addition, in April 2014, we announced our planned initial public offering in the United Kingdom of the ordinary shares of our newly-formed subsidiary, BBI Diagnostics. When complete, we expect that these steps will not only sharpen our focus on our mission of enabling healthcare providers to improve clinical outcomes and lower costs, but will also reduce indebtedness and enhance shareholder value.

Financial Highlights

 

    Net revenue decreased by $22.6 million, or 3%, to $716.6 million for the three months ended March 31, 2014, from $739.2 million for the three months ended March 31, 2013.

 

    Gross profit decreased by $13.0 million, or 4%, to $351.2 million for the three months ended March 31, 2014, from $364.3 million for the three months ended March 31, 2013.

 

    For the three months ended March 31, 2014, we generated a net loss available to common stockholders of $11.5 million, or $0.14 per basic and diluted common share, compared to net income available to common stockholders of $7.2 million, or $0.09 per basic and diluted common share, for the three months ended March 31, 2013.

Results of Operations

Where discussed, results excluding the impact of foreign currency translation are calculated on the basis of local currency results, using foreign currency exchange rates applicable to the earlier comparative period. We believe presenting information using the same foreign currency exchange rates helps investors isolate the impact of changes in those rates from other trends. Our results of operations were as follows:

Net Product Sales and Services Revenue, Total and by Business Segment. Total net product sales and services revenue decreased by $23.8 million, or 3%, to $711.4 million for the three months ended March 31, 2014, from $735.2 million for the three months ended March 31, 2013. Net product sales and services revenue decreased primarily as a result of decreased U.S. influenza revenues due to the relatively short 2013-2014 flu season and a reduction in U.S. healthcare utilization. Excluding the impact of currency translation, net product sales and services revenue for the three months ended March 31, 2014 decreased by $21.2 million, or 3%, compared to the three months ended March 31, 2013. Net product sales and services revenue by business segment for the three months ended March 31, 2014 and 2013 are as follows (in thousands):

 

     Three Months Ended March 31,      % Change  
     2014      2013     

Professional diagnostics

   $ 561,333       $ 578,628         (3 )% 

Health information solutions

     123,668         134,207         (8 )% 

Consumer diagnostics

     26,409         22,350         18
  

 

 

    

 

 

    

Net product sales and services revenue

   $ 711,410       $ 735,185         (3 )% 
  

 

 

    

 

 

    

Professional Diagnostics

The following table summarizes our net product sales and services revenue from our professional diagnostics business segment by groups of similar products and services for the three months ended March 31, 2014 and 2013 (in thousands):

 

     Three Months Ended March 31,      % Change  
     2014      2013     

Infectious disease

   $ 164,030       $ 189,844         (14 )% 

Toxicology

     151,897         149,049         2

Cardiology

     121,633         114,933         6

Diabetes

     50,721         50,083         1

Other

     73,052         74,719         (2 )% 
  

 

 

    

 

 

    

Professional diagnostics net product sales and services revenue

   $ 561,333       $ 578,628         (3 )% 
  

 

 

    

 

 

    

Net product sales and services revenue from our professional diagnostics business segment decreased by $17.3 million, or 3%, to $561.3 million for the three months ended March 31, 2014, from $578.6 million for the three months ended March 31, 2013. Excluding the impact of currency translation, net product sales and services revenue from our professional diagnostics business segment decreased by $14.3 million, or 2%, comparing the three months ended March 31, 2014 to the three months ended March 31,

 

30


Table of Contents

2013. Revenue decreased primarily as a result of a $27.1 million decrease in our U.S. flu-related net product sales from $34.3 million during the three months ended March 31, 2013 to $7.3 million during the three months ended March 31, 2014. This decrease was partially offset by $21.5 million in non-currency-adjusted incremental revenues attributable to acquisitions and a $6.4 million decrease in net revenue as a result of our 2013 disposition of Spinreact. Net product sales of Alere Triage® meter-based products in the U.S. increased for the first time since our supply issues began in the second quarter of 2012 to $22.9 million during the three months ended March 31, 2014 from $21.6 million during the three months ended March 31, 2013. Primarily driving the increase in revenues from Triage meter-based sales were increased sales of our BNP, Cardiac Panel and D-dimer products. Revenue from mail order diabetes sales decreased by $0.9 million, or 3%, to $32.3 million for the three months ended March 31, 2014 from $33.2 million for the three months ended March 31, 2013, primarily as a result of a reduction in the Center for Medicare & Medicaid Services’ reimbursement rates for those products, which became effective on July 1, 2013, the effect of which was partially offset by an increase in patients served from 282,000 at the end of the first quarter of 2013 to 769,000 as of March 31, 2014. Excluding the impact of acquisitions, the increase in net product sales from meter-based Triage products in the U.S., the impact of the decrease in flu-related sales during the comparable periods, and the decrease in organic revenues from our U.S. mail order diabetes business impacted by the reduction in CMS’ reimbursement rates which became effective on July 1, 2013, the currency-adjusted organic growth for our professional diagnostics net product sales and services revenue was approximately $18.4 million, or 4%, from the three months ended March 31, 2013 to the three months ended March 31, 2014.

Within our professional diagnostics business segment, net product sales and services revenue for our cardiology business increased by approximately $6.7 million, or 6%, to $121.6 million for the three months ended March 31, 2014, from $114.9 million for the three months ended March 31, 2013. The increase during the first quarter of 2014 was principally driven by an increase in sales of our Triage, Cholestech LDX and epoc products, offset by a decline in sales of our Alere INRatio2 PT/INR professional test strip in the U.S. due to a voluntary recall. Net product sales and services revenue for our infectious disease business decreased by approximately $25.8 million, or 14%, to $164.0 million for the three months ended March 31, 2014, from $189.8 million for the three months ended March 31, 2013. The decrease was primarily due to a larger-than-expected reduction in U.S. healthcare utilization during the first quarter of 2014, as compared to the first quarter of 2013. Net product sales and services revenue for our toxicology business increased by approximately $2.9 million, or 2%, to $151.9 million for the three months ended March 31, 2014, from $149.0 million for the three months ended March 31, 2013. Our diabetes business increased by approximately $0.6 million, or 1%, to $50.7 million for the three months ended March 31, 2014, from $50.1 million for the three months ended March 31, 2013. The increase was primarily the result of our recent acquisitions of the Medicare fee-for-service assets of Liberty Medical, or the Liberty business, and Simplex Healthcare, Inc., or Simplex, which contributed a combined net $21.1 million of the non-currency adjusted incremental revenue, offsetting the decline in revenue attributable to the reduction in CMS’s reimbursement rates described above. Included in the $50.7 million of revenue from our diabetes business for the three months ended March 31, 2014 were $32.3 million of mail order diabetes sales, compared to $33.2 million for the three months ended March 31, 2013.

Health Information Solutions

The following table summarizes our net product sales and services revenue from our health information solutions business segment by groups of similar products and services for the three months ended March 31, 2014 and 2013 (in thousands):

 

     Three Months Ended March 31,      % Change  
     2014      2013     

Condition and case management

   $ 49,319       $ 54,126         (9 )% 

Wellness

     24,950         26,300         (5 )% 

Women’s and children’s health

     22,215         29,080         (24 )% 

Patient self-testing services

     27,184         24,701         10
  

 

 

    

 

 

    

Health information solutions net product sales and services revenue

   $ 123,668       $ 134,207         (8 )% 
  

 

 

    

 

 

    

Our health information solutions net product sales and services revenue decreased by $10.5 million, or 8%, to $123.7 million for the three months ended March 31, 2014, from $134.2 million for the three months ended March 31, 2013, as a result of the challenging contracting season in the second half of 2013. Within our health information solutions business segment, net product sales and services revenues from our condition and case management, wellness and women’s and children’s health businesses each decreased during the three months ended March 31, 2014, compared to the three months ended March 31, 2013, as we experienced customer terminations, lower state enrollments in wellness programs and lower revenue from homecare services in these businesses. Our patient self-testing services net product sales and services revenue increased approximately $2.5 million, or 10%, to $27.2 million for the three months ended March 31, 2014, from $24.7 million for the three months ended March 31, 2013, principally driven by an increase in our home coagulation monitoring programs resulting from a larger patient population and a simultaneous reduction in customer attrition rates.

 

31


Table of Contents

Consumer Diagnostics

Net product sales and services revenue from our consumer diagnostics business segment revenue increased by $4.1 million, or 18%, to $26.4 million for the three months ended March 31, 2014, from $22.4 million for the three months ended March 31, 2013. The increase in revenue primarily resulted from an increase in our manufacturing revenue associated with SPD, as SPD successfully launched the Clearblue Advanced Pregnancy Test with Weeks Estimator product in the U.S. during 2013.

License and Royalty Revenue. License and royalty revenue represents license and royalty fees from intellectual property license agreements with third parties. License and royalty revenue increased by approximately $1.1 million, or 28%, to $5.2 million for the three months ended March 31, 2014, from $4.1 million for the three months ended March 31, 2013. The increase in royalty revenue for the three months ended March 31, 2014, compared to the three months ended March 31, 2013, is primarily a result of higher royalties earned under existing licensing agreements.

Gross Profit and Margin Percentage. Gross profit decreased by $13.0 million, or 4%, to $351.2 million for the three months ended March 31, 2014, from $364.3 million for the three months ended March 31, 2013. The decrease in gross profit during the three months ended March 31, 2014, compared to the three months ended March 31, 2013, was largely attributed to the decrease in net product sales and services revenue principally resulting from weak U.S. influenza sales and a larger-than-expected reduction in U.S. healthcare utilization which primarily impacted our U.S. infectious disease revenue.

Cost of net revenue included amortization expense of $16.6 million and $19.2 million for the three months ended March 31, 2014 and 2013, respectively, and $0.5 million of non-cash charges relating to the write-up of inventory to fair value in connection with certain acquisitions during the three months ended March 31, 2013. Reducing gross profit for the three months ended March 31, 2014 and 2013 was $0.9 million and $0.6 million, respectively, in restructuring charges.

Overall gross margin was 49.0% of net revenue in the first quarter of 2014, compared to 49.3% in the first quarter of 2013. The lower gross margin in the current period principally reflects lower U.S. influenza sales and reduced mail-order diabetes reimbursement rates.

Gross Profit from Net Product Sales and Services Revenue, Total and by Business Segment. Gross profit from net product sales and services revenue decreased by $14.4 million, or 4%, to $347.6 million for the three months ended March 31, 2014, from $361.9 million for the three months ended March 31, 2013. Gross profit from net product sales and services revenue by business segment for the three months ended March 31, 2014 and 2013 is as follows (in thousands):

 

     Three Months Ended March 31,      % Change  
     2014      2013     

Professional diagnostics

   $ 287,791       $ 300,175         (4 )% 

Health information solutions

     54,954         57,350         (4 )% 

Consumer diagnostics

     4,821         4,424         9
  

 

 

    

 

 

    

Gross profit from net product sales and services revenue

   $ 347,566       $ 361,949         (4 )% 
  

 

 

    

 

 

    

Professional Diagnostics

Gross profit from our professional diagnostics net product sales and services revenue decreased by $12.4 million, or 4%, to $287.8 million for the three months ended March 31, 2014, compared to $300.2 million for the three months ended March 31, 2013. The lower gross profit in the current period principally reflects the lower U.S. influenza sales and reduced mail-order diabetes reimbursement rates. Cost of professional diagnostics net product sales and services revenue during the three months ended March 31, 2013 included a non-cash charge of $0.5 million relating to the write-up of inventory to fair value in connection with certain acquisitions. Reducing gross profit during the three months ended March 31, 2014 and 2013 was $0.8 million and $0.2 million, respectively, in restructuring charges.

Cost of professional diagnostics net product sales and services revenue included amortization expense of $15.1 million and $17.4 million during the three months ended March 31, 2014 and 2013, respectively.

As a percentage of our professional diagnostics net product sales and services revenue, gross margin for the three months ended March 31, 2014 and 2013 was 51% and 52%, respectively. The lower gross margin in the current period principally reflects the lower U.S. influenza sales and reduced mail-order diabetes reimbursement rates.

 

32


Table of Contents

Health Information Solutions

Gross profit from our health information solutions net product sales and services revenue decreased by $2.4 million, or 4%, to $55.0 million for the three months ended March 31, 2014, compared to $57.4 million for the three months ended March 31, 2013. Reducing gross profit during the three months ended March 31, 2014 and 2013 was $0.1 million and $0.4 million in restructuring charges.

Cost of health information solutions net product sales and services revenue included amortization expense of $1.4 million and $1.5 million during the three months ended March 31, 2014 and 2013, respectively.

As a percentage of our health information solutions net product sales and services revenue, gross margin for the three months ended March 31, 2014 and 2013 was 44% and 43%, respectively. The one percentage point increase in gross margin was primarily due to operational efficiencies realized during the three months ended March 31, 2014 within the condition and case management business as a result of various restructuring plans.

Consumer Diagnostics

Gross profit from our consumer diagnostics net product sales and services revenue increased by $0.4 million, or 9%, to $4.8 million for the three months ended March 31, 2014, compared to $4.4 million for the three months ended March 31, 2013. The increase in gross profit was primarily the result of an increase in manufacturing revenue, as discussed above.

Cost of consumer diagnostics net product sales and services revenue included amortization expense of $0.1 million and $0.3 million during the three months ended March 31, 2014 and 2013, respectively.

As a percentage of consumer diagnostics net product sales and services revenue, gross margin for the three months ended March 31, 2014 and 2013 was 18% and 20%, respectively.

Research and Development Expense. Research and development expense decreased by $2.8 million, or 7%, to $38.7 million for the three months ended March 31, 2014, from $41.5 million for the three months ended March 31, 2013. Research and development expense during the three months ended March 31, 2014 and 2013 is reported net of grant funding of $2.1 million and $0.5 million, respectively, arising from the research and development funding relationship with the Bill and Melinda Gates Foundation that we entered into in February 2013. Included in research and development expense for the three months ended March 31, 2013 were restructuring charges totaling approximately $0.6 million associated with our various restructuring plans to integrate our newly-acquired businesses. Amortization expense of $1.2 million and $1.3 million was included in research and development expense for the three months ended March 31, 2014 and 2013, respectively.

Research and development expense as a percentage of net revenue was 5% and 6% for the three months ended March 31, 2014 and 2013, respectively.

Sales and Marketing Expense. Sales and marketing expense decreased by $9.4 million, or 6%, to $147.1 million for the three months ended March 31, 2014, from $156.5 million for the three months ended March 31, 2013. The decrease was primarily driven by lower amortization expense during the three months ended March 31, 2014, compared to the three months ended March 31, 2013. Amortization expense of $45.0 million and $53.5 million was included in sales and marketing expense for the three months ended March 31, 2014 and 2013, respectively. Restructuring charges associated with our various restructuring plans to integrate our newly-acquired businesses totaling approximately $1.6 million and $1.1 million were included in sales and marketing expense for the three months ended March 31, 2014 and 2013, respectively.

Sales and marketing expense as a percentage of net revenue was 21% for each of the three-month periods ended March 31, 2014 and 2013.

General and Administrative Expense. General and administrative expense increased by approximately $3.7 million, or 3%, to $139.5 million for the three months ended March 31, 2014, from $135.9 million for the three months ended March 31, 2013. The increase was primarily attributable to a $2.6 million increase in restructuring plans to integrate our newly-acquired businesses and a $1.7 million increase in amortization expense, as well as the inclusion in general and administrative expense for the three months ended March 31, 2014 of $3.0 million of costs associated with potential business dispositions, which were partially offset by a $0.6 million decrease in acquisition-related costs in the three months ended March 31, 2014.

General and administrative expense as a percentage of net revenue was 19% and 18% for the three months ended March 31, 2014 and 2013, respectively.

Interest Expense. Interest expense includes interest charges and the amortization of deferred financing costs and original issue discounts associated with certain debt issuances. Interest expense decreased by $5.4 million, or 9%, to $52.0 million for the three months ended March 31, 2014, from $57.4 million for the three months ended March 31, 2013. The decrease is principally due to

 

33


Table of Contents

lower interest expense recorded in connection with lower outstanding debt balances during the first quarter of 2014 compared to the first quarter of 2013. Also contributing to the decrease was the lower interest rate associated with our 6.5% senior subordinated notes issued in May 2013, compared to the interest rate associated with our 9% senior subordinated notes which we redeemed in the second quarter of 2013.

Other Income (Expense), Net. Other income (expense), net includes interest income, realized and unrealized foreign exchange gains and losses, and other income and expense. The components and the respective amounts of other income (expense), net are summarized as follows (in thousands):

 

     Three Months Ended March 31,     Change  
     2014     2013    

Interest income

   $ 384      $ 1,023      $ (639

Foreign exchange gains (losses), net

     5,267        (467     5,734   

Other

     (929     (1,026     97   
  

 

 

   

 

 

   

 

 

 

Total other income (expense), net

   $ 4,722      $ (470   $ 5,192   
  

 

 

   

 

 

   

 

 

 

Other expense of $0.9 million for the three months ended March 31, 2014 included a $1.5 million reversal of legal settlement accruals, offset by a $1.8 million write-down on a receivable and $0.6 million in losses on disposals of fixed assets.

Benefit for Income Taxes. The benefit for income taxes decreased by $27.0 million to a $9.9 million benefit for the three months ended March 31, 2014, from a $36.9 million benefit for the three months ended March 31, 2013. The effective tax rate for the three months ended March 31, 2014 and 2013 was 46.4% and 134.7%, respectively. Our effective tax rate is calculated based on projected income across many different jurisdictions, and can change based on the location of income, losses and credits. The decrease in the effective tax rate from the three months ended March 31, 2013 to the three months ended March 31, 2014 is primarily a result of the following: (i) our forecasted jurisdictional mix of income, (ii) losses on contingent consideration fair value adjustments, (iii) loss entity valuation allowance changes, and (iv) U.S. federal research and development tax credits included in our 2013 tax benefit that are not included in 2014.

Equity Earnings of Unconsolidated Entities, Net of Tax. Equity earnings of unconsolidated entities is reported net of tax and includes our share of earnings in entities that we account for under the equity method of accounting. Equity earnings of unconsolidated entities, net of tax for the three months ended March 31, 2014 reflect the following: (i) our 50% interest in SPD in the amount of $5.1 million, (ii) our 40% interest in Vedalab S.A., or Vedalab, in the amount of $0.1 million and (iii) our 49% interest in TechLab, Inc., or TechLab, in the amount of $0.3 million. Equity earnings of unconsolidated entities, net of tax for the three months ended March 31, 2013 reflect the following: (i) our 50% interest in SPD in the amount of $2.5 million, (ii) our 40% interest in Vedalab in the amount of $0.2 million and (iii) our 49% interest in TechLab in the amount of $0.2 million.

Net Income (Loss) Available to Common Stockholders. For the three months ended March 31, 2014, we generated a net loss available to common stockholders of $11.5 million, or $0.14 per basic and diluted common share. For the three months ended March 31, 2013, we generated a net income available to common stockholders of $7.2 million, or $0.09 per basic and diluted common share. Net income (loss) available to common stockholders reflects $5.3 million of preferred stock dividends paid during each of the three-month periods ended March 31, 2014 and 2013. See Note 6 of the accompanying Consolidated Financial Statements for the calculation of net income (loss) per common share.

Liquidity and Capital Resources

Based upon our current working capital position, current operating plans and expected business conditions, we expect to fund our short- and long-term working capital needs primarily using existing cash and our operating cash flow, and we expect our working capital position to improve as we improve our future operating margins and grow our business through new product and service offerings and by continuing to leverage our strong intellectual property position. Additionally, we remain engaged in discussions concerning divestitures of our non-core businesses in order to pay down outstanding debt. As of March 31, 2014, we had $433.0 million of cash and cash equivalents, of which $121.0 million was held by domestic subsidiaries and $312.0 million was held by foreign entities. We generally do not plan to repatriate cash held by foreign entities due to adverse tax implications, including incremental U.S. tax liabilities and potential foreign withholding tax liabilities.

We may also utilize our secured credit facility or other new sources of financing to fund a portion of our capital needs and other commitments, including our contractual contingent consideration obligations and future acquisitions. As of March 31, 2014, we had outstanding borrowings totaling $170.0 million under the $250.0 million revolving line of credit under our secured credit facility,

 

34


Table of Contents

leaving $80.0 million available to us for additional borrowings. The terms and conditions of our outstanding debt instruments also contain covenants which expressly restrict our ability to incur additional indebtedness and conduct other financings. As of March 31, 2014, we had $3.8 billion in outstanding indebtedness comprised of $2.3 billion under our secured credit facility, including borrowings under our revolving line of credit, $450.0 million of 7.25% senior notes due 2018, $400.0 million of 8.625% senior subordinated notes due 2018, $425.0 million of 6.5% senior subordinated notes due 2020, and $150.0 million of 3% convertible senior subordinated notes due 2016. In February 2013, we redeemed the $1.8 million outstanding principal amount of our 7.875% senior notes pursuant to our optional redemption right under the indenture under which the 7.875% senior notes were issued.

If the capital and credit markets experience volatility or the availability of funds is limited, we may incur increased costs associated with issuing debt instruments. In addition, it is possible that our ability to access the capital and credit markets could be limited by these or other factors at a time when we would like, or need, to do so, which could have an adverse impact on our ability to refinance maturing debt and/or react to changing economic and business conditions.

Our funding plans for our working capital needs and other commitments may be adversely impacted by unexpected costs associated with the pending public offering of BBI Diagnostics, integrating the operations of newly-acquired companies, executing our cost-savings strategies and prosecuting and defending our existing lawsuits and/or unforeseen lawsuits against us. We also cannot be certain that our underlying assumed levels of revenues and expenses will be realized. In addition, we intend to continue to make investments in our research and development efforts related to the substantial intellectual property portfolio we own. We may also choose to further expand our research and development efforts and may pursue the acquisition of new products and technologies through licensing arrangements, business acquisitions, or otherwise. We may also choose to make significant investment to pursue legal remedies against potential infringers of our intellectual property rights. If we decide to engage in such activities, or if our operating results fail to meet our expectations, we could be required to seek additional funding through public or private financings or other arrangements. In such event, adequate funds may not be available when needed or may be available only on terms which could have a negative impact on our business and results of operations. In addition, if we raise additional funds by issuing equity or convertible securities, dilution to then-existing stockholders may result.

 

     Three Months Ended March 31,  

Cash Flow Summary (in thousands)

   2014     2013  

Net cash provided by operating activities

   $ 105,908      $ 71,061   

Net cash used in investing activities

     (24,259     (196,754

Net cash provided by (used in) financing activities

     (11,026     131,568   

Foreign exchange effect on cash and cash equivalents

     495        (6,988
  

 

 

   

 

 

 

Net increase (decrease) in cash and cash equivalents

     71,118        (1,113

Cash and cash equivalents, beginning of period

     361,908        328,346   
  

 

 

   

 

 

 

Cash and cash equivalents, end of period

   $ 433,026      $ 327,233   
  

 

 

   

 

 

 

Summary of Changes in Cash Position

As of March 31, 2014, we had cash and cash equivalents of $433.0 million, a $71.1 million increase from December 31, 2013. Our primary sources of cash during the three months ended March 31, 2014 included $105.9 million generated by our operating activities, $14.7 million of cash received from common stock issuances under employee stock option and stock purchase plans, $4.4 million received from disposition of our Spinreact operations and a $2.2 million reduction in restricted cash. Our primary uses of cash during the three months ended March 31, 2014 were $27.5 million of capital expenditures, $15.8 million related to the repayment of long-term debt obligations, $5.3 million for cash dividends paid on our Series B Preferred Stock, $4.2 million related to payments of acquisition-related contingent consideration obligations, and $2.9 million related to an increase in other assets. Fluctuations in foreign currencies favorably impacted our cash balance by $0.5 million during the three months ended March 31, 2014.

As of March 31, 2013, we had cash and cash equivalents of $327.2 million, a $1.1 million decrease from December 31, 2012. Our primary sources of cash during the three months ended March 31, 2013 included $162.5 million of net proceeds under various revolving credit facilities, which included $170.0 million borrowed against our secured credit facility revolving line-of-credit, $71.1 million generated by our operating activities, a $10.8 million return of capital from SPD, $10.1 million received from long-term debt borrowings, and $6.1 million of cash received from common stock issuances under employee stock option and stock purchase plans. Our primary uses of cash during the three months ended March 31, 2013 were $158.4 million net cash paid for acquisitions, $36.1 million of capital expenditures, $19.6 million related to the repayment of long-term debt obligations, $19.1 million related to payments of acquisition-related contingent consideration obligations, $5.6 million related to an increase in other assets, an $8.6 million increase in restricted cash, and $5.3 million for cash dividends paid on our Series B Preferred Stock. Fluctuations in foreign currencies negatively impacted our cash balance by $7.0 million during the three months ended March 31, 2013.

 

35


Table of Contents

Cash Flows from Operating Activities

Net cash provided by operating activities during the three months ended March 31, 2014 was $105.9 million, which resulted from a net loss of $6.1 million, $77.1 million of non-cash items and $34.9 million of cash provided by changes in net working capital requirements during the period. The $77.1 million of non-cash items included, among other items, $98.1 million related to depreciation and amortization, $5.7 million related to non-cash stock-based compensation, $4.1 million of interest expense related to the amortization of deferred financing costs and original issue discounts and a $2.1 million loss on the disposition of fixed assets, partially offset by a $24.6 million decrease related to changes in our deferred tax assets and liabilities, which resulted in part from amortization of intangible assets, $5.4 million in equity earnings in unconsolidated entities, net of tax and $3.7 million related to other non-cash items.

Net cash provided by operating activities during the three months ended March 31, 2013 was $71.1 million, which resulted from net income of $12.4 million, $63.0 million of non-cash items and $4.4 million of cash utilized by changes in net working capital requirements during the period. The $63.0 million of non-cash items included, among other items, $105.0 million related to depreciation and amortization, $5.2 million of interest expense related to the amortization of deferred financing costs and original issue discounts, $4.1 million related to non-cash stock-based compensation, and $1.9 million related to other non-cash items, partially offset by a $50.9 million decrease related to changes in our deferred tax assets and liabilities, which resulted in part from amortization of intangible assets, and $2.9 million in equity earnings in unconsolidated entities, net of tax.

Cash Flows from Investing Activities

Our investing activities during the three months ended March 31, 2014 utilized $24.3 million of cash, including $27.5 million of capital expenditures, $2.9 million related to an increase in other assets, and $0.5 million paid for equity method investments, partially offset by $4.4 million received from disposition of our Spinreact operations and a $2.2 million decrease in restricted cash.

Our investing activities during the three months ended March 31, 2013 utilized $196.8 million of cash, including $158.4 million net cash paid for acquisitions, $36.1 million of capital expenditures, an increase in our restricted cash balance of $8.6 million which was principally driven by $7.9 million of cash received from the Bill and Melinda Gates Foundation and $5.6 million related to an increase in other assets, partially offset by a $10.8 million return of capital from SPD and $1.1 million of proceeds received from the sale of property, plant and equipment.

Cash Flows from Financing Activities

Net cash used in financing activities during the three months ended March 31, 2014 was $11.0 million. Financing activities during the three months ended March 31, 2014 primarily included approximately $15.8 million for the payment of long-term debt obligations, $5.3 million for dividend payments related to our Series B preferred stock, $4.2 million for payments of acquisition-related contingent consideration obligations, and $1.8 million for payment of capital lease obligations. We received approximately $14.7 million of cash from common stock issuances under employee stock option and stock purchase plans and $0.9 million from long-term debt borrowings.

Net cash provided by financing activities during the three months ended March 31, 2013 was $131.6 million. Financing activities during the three months ended March 31, 2013 primarily included approximately $162.5 million of net proceeds under various revolving credit facilities, which included $170.0 million borrowed against our secured credit facility revolving line-of-credit, $10.1 million received from long-term debt borrowings and $6.1 million of cash received from common stock issuances under employee stock option and stock purchase plans. We utilized approximately $19.6 million for the payment of long-term debt obligations, $19.1 million for payments of acquisition-related contingent consideration obligations, $5.3 million for dividend payments related to our Series B preferred stock, $1.7 million for payment of capital lease obligations and $1.4 million related to the payment of debt-related financing costs.

As of March 31, 2014, we had an aggregate of $21.3 million in outstanding capital lease obligations which are payable through 2019.

Income Taxes

As of December 31, 2013, we had approximately $87.4 million of domestic net operating loss, or NOL, and domestic capital loss carryforwards, approximately $998.8 million of state NOL carryforwards and $254.7 million of foreign NOL and foreign capital loss carryforwards, which either expire on various dates through 2033 or can be carried forward indefinitely. As of December 31, 2013, we had approximately $70.4 million of domestic research and development, foreign tax and alternative minimum tax credits which either expire on various dates through 2033 or can be carried forward indefinitely. These loss carryforwards and tax credits may be available to reduce future federal, state and foreign taxable income, if any, and are subject to review and possible adjustment by the appropriate tax authorities.

 

36


Table of Contents

Furthermore, all domestic losses and credits are subject to the limitations imposed by Sections 382 and 383 of the Internal Revenue Code, and may be limited in the event of certain cumulative changes in ownership interests of significant shareholders over a three-year period in excess of 50%. Sections 382 and 383 impose an annual limitation on the use of these losses or credits to an amount equal to the value of the company at the time of the ownership change multiplied by the long-term tax exempt rate. We have recorded a valuation allowance against a portion of the deferred tax assets related to our NOLs and credits and certain of our other deferred tax assets to reflect uncertainties that might affect the realization of such deferred tax assets, as these assets can only be realized via profitable operations.

Off-Balance Sheet Arrangements

We had no material off-balance sheet arrangements as of March 31, 2014.

Contractual Obligations

As of March 31, 2014, our contractual obligations have not changed significantly since December 31, 2013, as presented in our Annual Report on Form 10-K, as amended, for the year ended December 31, 2013.

Critical Accounting Policies

The discussion and analysis of our financial condition and results of operations are based on our Consolidated Financial Statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements in accordance with generally accepted accounting principles requires us to make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On a quarterly basis, we evaluate our estimates, including those related to revenue recognition and related allowances, bad debt, inventory, valuation of long-lived assets, including intangible assets and goodwill, income taxes, including any valuation allowance for our net deferred tax assets, contingencies and litigation, and stock-based compensation. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions.

There have been no significant changes in our critical accounting policies or management estimates since December 31, 2013. A comprehensive discussion of our critical accounting policies and management estimates is included in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K, as amended, for the year ended December 31, 2013.

Recent Accounting Pronouncements

See Note 17 in the Notes to the Consolidated Financial Statements included in this Quarterly Report on Form 10-Q, regarding the impact of certain recent accounting pronouncements on our Consolidated Financial Statements.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our market risks, and the ways we manage them, are summarized in Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk” of our Annual Report on Form 10-K, as amended, for the year ended December 31, 2013. There have been no material changes in the three months ended March 31, 2014 to our market risks or our management of such risks.

 

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

        Our management evaluated, with the participation of our Chief Executive Officer (CEO) and Chief Financial Officer (CFO), the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our management, including the CEO and CFO, concluded that our disclosure controls and procedures were effective at that time. We and our management understand nonetheless that controls and procedures, no matter how well designed and operated, can provide only reasonable assurances of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating and implementing possible controls and procedures. In reaching their conclusions stated above regarding the effectiveness of our disclosure controls and procedures, our CEO and CFO concluded that such disclosure controls and procedures were effective as of such date at the “reasonable assurance” level.

 

37


Table of Contents

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the most recent fiscal quarter covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

 

ITEM 1A. RISK FACTORS

We may not complete our pending initial public offering of BBI Diagnostics Group plc.

In April 2014, we announced plans for an initial public offering in the United Kingdom of the ordinary shares of BBI Diagnostics Group plc, or BBI Diagnostics, a new subsidiary formed for purposes of the offering. We expect to sell a 25% ownership interest in BBI Diagnostics in the offering. We expect that the business of BBI Diagnostics will include (i) substantially all of the operations of the BBI Holdings group of companies, including its reagent manufacturing, biothreat detection and healthcare businesses; (ii) the laboratory immunoassay business of the Axis-Shield group of companies; (iii) our 50% interest in SPD; (iv) the First Check consumer diagnostics business; and (v) the Bionote animal health diagnostics business. The offering is subject to completion of ongoing regulatory review, satisfactory market conditions, receipt of all necessary approvals, including approvals from the lenders under our secured credit facility and the holders of notes outstanding under our various indentures, and other conditions. There can be no assurance regarding the ultimate timing of the proposed transaction or that the transaction will be completed. Additionally, even if the proposed transaction is completed, we have agreed, among other things, that BBI Diagnostics will have a majority of independent directors and that we will deal with it on an arms-length basis and on normal commercial terms. Further, BBI Diagnostics will be required to comply with the listing rules and other regulatory requirements applicable to listed companies in the United Kingdom. Accordingly, we expect to have diminished influence over the future operations of BBI Diagnostics following the offering.

 

ITEM 6. EXHIBITS

Exhibits:

 

Exhibit
No.

 

Description

  *31.1   Certification by Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
  *31.2   Certification by Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
  *32.1   Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
*101   Interactive Data Files regarding (a) our Consolidated Statements of Operations for the Three Months Ended March 31, 2014 and 2013, (b) our Consolidated Statements of Comprehensive Loss for the Three Months Ended March 31, 2014 and 2013, (c) our Consolidated Balance Sheets as of March 31, 2014 and December 31, 2013, (d) our Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2014 and 2013 and (e) the Notes to such Consolidated Financial Statements.

 

* Filed herewith

 

38


Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

      ALERE INC.
Date: May 6, 2014      

/s/ Carla R. Flakne

      Carla R. Flakne
      Chief Accounting Officer and an authorized officer

 

39